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Te activation of auto-aggressive T cells is  crucial  for the development of
autoimmune diseases,  such as multiple sclerosis (MS) or its animal model
experimental autoimmune encephalomyelitis  (EAE).  T cell  activation relies
on stimulation of the T cell receptor by antigen and results in rapid release of
calcium (Ca2+)  from the endoplasmic reticulum (ER) into the cytosol.  Tis
process is mediated by IP3 receptors and, possibly by ryanodine receptors
(RyRs). Te release of Ca2+ from the ER into the cytosol follows a second
infux of Ca2+ across the plasma membrane through Ca2+  release activated
Ca2+  channels (CRAC). Tis store-operated calcium entry (SOCE) mediates
further signal transduction by the activation of Ca2+ sensitive enzymes, such
as calcineurin, which then leads to transcription and production of T cell
characteristic cytokines.
Even though EAE in mice is in many aspects a well studied model, the role of
RyRs has not yet been addressed in context of the disease. Previous studies
using loss-of-function techniques unveiled the importance of RyR1 and RyR3
for  NAADP  mediated  Ca2+ signaling  in  Jurkat  cells,  and  in  rat  adoptive
transfer EAE by pharmacological antagonism of NAADP, a putative ligand
for RyR1.
In the present study we found that the gene encoding for the RyR1 isoform is
expressed in antigen-experienced efector,  but  not  in naïve mouse T cells.
Genetic deletion of Ryr1 studied in fetal liver chimeric mice did not result in
overt  immune  phenotype,  however  Ryr1 defcient  T lymphocytes  show
diminished  Ca2+  signaling  and  reduced  proliferation  in  response  to  TCR
stimulation. Tis supported the observation that these animals developed less
severe active EAE than control mice.
Although our data indicate that Ryr3 does not play a major role in T cells,
yet we observed atenuated clinical EAE and CNS histopathology in mice
with a  whole-body knockout  for  the  Ryr3 gene.  Tere however,  we have
excluded  that  Ryr3 defciency  in  T cells  is  responsible  for  mitigated
neuroinfammation  using  chimeric  mice  and  T cell  transfer  experiments.
Instead  we  observed  that  Ryr3  defcient  astrocytes  display  alteration  in
stimulated Ca2+ signaling  in vitro,  produce less chemokines in response to
infammatory stimuli in vitro but also in the infamed CNS tissue, that limits
infltration  of  immune  cells  and  associated  tissue  damage.  We  also
demonstrate that pharmacological inhibition of RyR function has benefcial
efects on the EAE disease. Tus, ryanodine receptors seem to play critical
roles during autoimmune disease of the CNS (RyR1 in T cells whereas RyR3




Multiple  sclerosis  (MS)  is  a  chronic  autoimmune  disorder  afecting  the
central  nervous  system  (CNS),  where  the  immune  system  damages  and
destroys the protecting myelin sheaths of the neurons in brain and spinal
cord, resulting in demyelination and axonal loss (CALABRESI, 2004, LOMA and
HEYMAN, 2011). Te disease then manifests in cortical lesions (plaques) in the
brain’s white mater. It is the most commonly diagnosed neurologic disease
in young adults at ages between 20 and 40, occurring twice as frequently in
women as in men. Te total number of individuals with MS is estimated to
around  2.5 million  worldwide  (COMPSTON AND COLES,  2008).  Te  disease
appears highly heterogenic in terms of clinical symptoms, disease course and
pathology,  as  well  as  the  response  to  therapies.  MS  symptoms  are  very
variable  and  afect  each  patient  diferently.  Te  frst  symptoms,  used  to
identify MS, commonly present as blurred vision, and impairment of mobility
and balance (due  to  muscle  atrophy).  Patients  with  established MS sufer
from  increasing  gait  abnormalities,  loss  of  vision  and  impaired  body
coordination that may worsen over time to a severe paralysis. In addition,
extreme  fatigue,  bladder  dysfunction  and  pain  can  occur  during  MS
(GOLDENBERG,  2012; CREE,  2014).  Te  cause  of  MS  is  unknown,  but  a
combination  of  genetic  susceptibility  and  a  non-genetic  triggers  are
discussed (BARCELLOS et al.,  2003,  WILLER et al., 2003,  HANDEL et al., 2010).
First  degree  relatives  and  twins  are  40-fold  more  susceptible  to  MS
suggesting a genetic basis (BARCELLOS et  al.,  2003).  Exposure to infectious
agents like viruses, e.g. Epstein-Barr-Virus, or some mycoplasma strains, e.g.
mycoplasma pneumoniae,  but also smoking or sunlight exposure/vitamin D
levels  are  discussed as  environmental  risk factors  that  can induce a  self-
sustaining autoimmune disorder and favoring MS (CREE, 2014).
According to its disease progress, MS is categorized into four major variants
(HAUSER and GOODWIN, 2008):
1. Relapsing-remiting MS (RRMS): With a prevalence of 85 %, RRMS is
the  most  occurring  form  of  MS,  characterized  by  abrupt  disease
phases (relapses) 1–2 times a year and disease-free phases, in that the
patients show improved or no symptoms (remission).
2. Secondary progressive MS (SPMS): Tis variant may develop in patients
with RRMS. In SPMS, patients sufer from continuous progression of
disability occurring afer a MS relapse.
3. Primary  progressive  MS  (PPMS): PPMS  afects  about  10 %  of  MS
patients.  It  is  characterized  by  continuous  disease  progression
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without any relapse or remission periods.
4. Progressive-relapsing MS (PRMS): About 5 % of  MS patients develop
this  rare  variant.  It  starts  directly  progressive,  with  intermediate
relapses but no remissions and straight worsening along the course of
disease.
Tere is no curative treatment for MS patients so far, partly due to the fact
that many aspects of MS etiology remain elusive. Current treatments focus
on modulation of the immune system but come along with signifcant side
efects  (LOMA and  HEYMAN,  2011).  Moreover,  long-term studies  on newer
therapies are pending. Terefore, conceiving the complex etiology of MS is
most important for an efective and safe treatment of MS patients.
1.2 Experimental autoimmune encephalomyelitis
Te  heterogeneity  of  MS  complicates  the  research.  To  understand  the
molecular and cellular mechanisms that drive the disease and to identify new
possible  therapeutic  targets  require  an  experimental  model  that  mimics
certain aspects of neuroinfammation relevant for MS. In rodents, there are
three  clinically  relevant  and  established  disease  models  of  MS.
Demyelination  evoked  by  viral  infection—such  as  Teiler's  Murine
Encephalitis  Virus or Semliki  Forest Virus—is a helpful  tool  to model the
viral  motive  of  MS  and  leads  to  a  progressive  CD4+ T cell  mediated
demyelinating disease (DONATI AND JACOBSON, 2002). Cuprizone treatment in
mice is a model of toxic demyelination and is evoked by feeding young mice
with the copper chelator cuprizone, that leads to oligodendrocyte death and
reversible demyelination (TORKILDSEN et al., 2008). Te most commonly used
animal  model  of  MS,  however,  is  experimental  autoimmune
encephalomyelitis  (EAE;  ROBINSON et  al.,  2014).  It  requires  active
immunization against myelin antigens (active EAE) or the adoptive transfer
of pathogenic efector T cells into naïve recipients (transfer EAE;  MILLER et
al., 2007). Active EAE is induced by the administration of myelin peptides,
such as  myelin  basic  protein  (MBP),  myelin oligodendrocyte  glycoprotein
(MOG) or proteolipid protein (PLP) in adjuvant in susceptible mouse strains.
By  contrast,  transfer  (‘passive’)  EAE  is  induced  by  transferring
encephalitogenic, myelin-specifc CD4+ T cell blasts into donor mice (MILLER
et al., 2007).
In active EAE, immunization against myelin antigens leads to the priming of
myelin-specifc  T cells  in  the  secondary  lymphoid  organs.  Succeeding
activation, T cells rapidly proliferate and diferentiate into efector cells and
become licensed to exit the secondary lymphoid organs through the eferent
2
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lymphatic vessels to enter the blood circulation. Te expression of adhesion
molecules and integrins allows T cells to overcome the blood-brain barrier
(BBB),  where they come in contact  with CNS-resident antigen presenting
cells  (APCs),  recognize  endogenously  expressed  antigens  and  become
reactivated.  Tis  leads  to  the  expression  and  secretion  of  the
proinfammatory  cytokines  IFN-γ,  IL-17,  GM-CSF  and  TNF-α  by  efector
T cells  (O’CONNOR et  al.,  2008;  KROENKE et  al.,  2008).  Tis  leads  to  a
disruption of the BBB and additional production of chemokines that in turn
facilitate  the  recruitment  of  monocytes,  macrophages,  neutrophils  and
γδT cells  into the CNS (GOVERMAN,  2009).  Tese infammatory cells  cause
and  mediate  damage  to  the  myelin  sheaths  and  axons,  and  are  mainly
responsible for the formation of lesions and the breakdown of the neuronal
network within the CNS.
In transfer EAE, activated myelin-specifc T1, T17 or mixed T1/T17 CD4+
T cell blasts from immunized donor mice are injected into naïve recipient
animals. By that, the efector phase of EAE can be modeled directly and it
also  allows the  tracking of  genetically  labeled encephalitogenic  T cells  in
vivo (JÄGER et al.,  2009). Te later approach is a powerful tool to analyze
T cell specifc roles of a gene of interest.
Mice develop variable forms of EAE depending on the genetic background of
the animals as well as the administered antigen. Active EAE induction with
MOG  protein  or  the  T cell  epitope  MOG35-55 (MEVGWYRSPFSRVVHLY
RNGK)  in  C57Bl/6  mice  leads  to  a  chronic  form  of  the  disease  starting
between days 9–12 post immunization with characteristic infammatory foci
appearing predominantly in the spinal cord rather than in brain (MENDEL et
al.,  1995).  In  contrast,  immunization  against  the  T cell  epitope  PLP139-151
(HCLGKWLGHPDKF) in SJL/J mice leads to a relapsing-remiting form of
EAE (MCRAE et al., 1992). Te generation of transgenic mice with deletion or
over-expression of immunological relevant genes enlarged the experimental
possibilities for studies on EAE. Examples of such genes are those encoding
T cell  receptors  (TCRs)  or  major  histocompatibility  complex  (MHC)
molecules.  Of  particular  interest  is  the  model  of  spontaneous  EAE.  Tis
specifc variant of EAE occurs in mice that were generated by crossing MOG-
specifc TCR transgenic mice with MOG-specifc Ig heavy-chain knock-in
mice with an incidence of 59 % (KRISHNAMOORTHY et al., 2006; BETTELLI et al.,
2006). Disease induction in these mice proceeds completely spontaneously
and overcomes the artifcial component of immunization or transfer of pre-
activated T lymphocytes. Tat brings it closer to the human disease MS and
is  of  great  advantage  when  studying  the  triggers  of  CNS  autoimmunity
(Betelli et al., 2006), however it is difcult to study early T cell infltration in




1.3 Te CNS and the blood-brain barrier
Te CNS is a highly specialized and complex organ in aspects of physiology,
neuroanatomy  and  immunology.  It  is  considered  as  ‘immune  privileged’,
even though this term is under debate among neuroscientists (CARSON et al.,
2006;  HARRIS et al.,  2014). Te immune privilege was frst described by Sir
Peter Brian Medawar in 1948, when he demonstrated that allografs from
mouse  skin  beter  persisted  in  eye  and  brain  than  in  tissues  from  the
periphery (MEDAWAR,  1948). For the CNS, immune privilege has been long
characterized by the lack of lymphatic vessels and a surrounding endothelial
barrier  restricting  immune  cell  contact  (ILIFF AND NEDERGAARD,  2013).
Furthermore, the low level expression of MHC molecules was considered as
another evidence for the brain being an immunologically privileged site. Yet,
as mentioned above, the term ‘immune privilege’ is under debate, because
recent  results  suggest  that  the  brain  is  capable  of  both  immune  and
autoimmune reactions as well (RIVEST et al., 2009). Tis was supported by the
discovery  of  MHC  molecule  expression  on  microglia  and  astrocytes
(NEUMANN et al.,  1996). While these cell populations usually express MHC
molecules only at low levels, up-regulated expression can be found under
infammatory  conditions  that  may  be  critical  for  antigen  presentation.
Reactive microglia and astrocytes with increased MHC-II expression have
been reported in several neurological diseases (MARAGAKIS AND ROTHSTEIN,
2006; MCGEER et al, 1993).
Te CNS is surrounded by the meninges, a set of membranes that consist of
three layers termed the dura mater, the arachnoid mater and the pia mater.
Te dura mater is the membrane closest to the skull (brain) or the epidural
space (spinal  cord).  Te arachnoid and pia  mater together are named the
leptomeninges.  Tey  form  the  subarachnoid  space  in  between,  which  is
occupied by the cerebrospinal fuid (CSF). Te CSF is produced in the choroid
plexus and circulates within the ventricular system of the brain. It provides
nutrients  and  acts  as  some  kind  of  fuid  dampening  system  additionally
protective for the brain. Te pia mater is the membrane that lies on the outer
surface  of  the  brain  and  spinal  cord.  Capillaries  from  blood  vessels  run
through the pia mater, thereby sustaining the CNS.
Te  blood-brain  barrier  (BBB)  is  separating  the  CNS  from  the  blood
circulation and is  composed  of  endothelial  cells,  an  underlying basement
membrane  and  the  astrocytic  endfeet.  Tese  astrocytic  foot  processes
associate with a second basement membrane to create the glia limitans (glial
limiting  membrane)  surrounding  the  endothelial  cells  of  the  BBB.  Tese
endothelial cells are connected by impermeable tight junctions that ensure
that the brain is being shielded from soluble molecules (including antibodies)
circulating through the blood vessels. Under neuroinfammatory conditions,
the astrocytes of the glia limitans and the endothelial cells are also known as
producers of chemokines and proinfammatory cytokines (CHOI et al., 2014). 
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1.4 Leukocyte infltration into the CNS
Te  migration  of  leukocytes  from  the  blood  circulation  into  infected  or
damaged tissue is called extravasation or diapedesis. In case of MS or EAE,
leukocytes frst have to overcome the BBB before entering the CNS.  Tis
makes it diferent from leukocyte extravasation in the periphery, where such
barriers  are  missing.  Several  routes  have  been  described  for  leukocyte
extravasation  into  the  CNS.  Te  major  one  is  from  the  blood  into  the
parenchymal  perivascular  space  through the  BBB,  while  a  second site  of
entry into the CNS is via the choroid plexus into the CSF (RANSOHOFF et al.,
2003).
Te  interplay  between  leukocytes  and  the  endothelium  of  the  BBB  that
fnally  leads  to  diapedesis  is  described  as  a  multistep  process,  in  which
diferent  certain  molecules  on  both  leukocytes  and  endothelial  cells  are
involved  (ENGELHARDT AND RANSOHOFF,  2012).  First,  leukocytes  come  in
contact with the endothelium. Tis step is termed ‘tethering’ or ‘capture’ and
is mediated by P-selectin glycoprotein ligand-1 (PSGL-1) on leukocytes and
its respective selectin counterparts on the vessel endothelium (AUSTRUP et al.,
1997).  Integrins—including  very  late  antigen-4  (VLA-4,  α4β1)  and
lymphocyte  function-associated  antigen  1  (LFA-1,  αLβ2)—as  well  as  the
adhesion  molecules  vascular  cell  adhesion  protein-1  (VCAM-1)  and
intercellular adhesion molecule-1 (ICAM-1) support capturing of leukocytes
and mediate the next step of leukocyte locomotion, which is the rolling of
leukocytes on the vessel endothelium (LEY et al., 2007). Rolling of leukocytes
comes  to  a  stop  once  leukocytes  recognize  glycosaminoglycan  bound
chemokines  on  the  endothelium  that  are  produced  locally  or  were
translocated  to  the  cellular  surface  (MIDDLETON et  al.,  2002).  Chemokine
binding  induces  conformational  changes  in  integrins,  leading  to  frm
adhesion  (‘atachment’)  of  leukocytes  to  the  vessel  endothelium.  Next,
leukocytes start to crawl—mainly against the blood fow—to locate a spot for
extravasation.  Tereby,  leukocytes  undergo  a  phenotypical  change  from
spherical to a rather fatened shape. Te frm adhesion is thereby necessary
due to constant shear stress of the blood fow (LAWRENCE et al., 1987). VLA-4
seems to be a crucial factor for intraluminal crawling, since treatment with
VLA-4  depleting  antibodies  prevented  leukocytes  from  crawling  and
extravasation, in contrast to LFA-1, whose depletion did not critically alter
leukocytes  transmigration (BARTHOLOMÄUS et  al.,  2009).  Finally,  diapedesis
can  occur  paracellular  through  endothelial  junctions,  or  transcellular
through the body of endothelial cells (LEY et al., 2007).
Afer successful diapedesis, leukocytes scan the leptomeningeal area for their
respective  antigen  and  come  in  contact  with  resident  perivascular  and
meningeal phagocytes, which are potential APCs. Afer recognition of the
antigen, leukocytes become reactivated. In case of T cells, they upregulate
proinfammatory  cytokines  (IFN-γ,  IL-17,  TNF-α,  and  IL-2)  and  surface
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markers (OX40, IL-2R;  BARTHOLOMÄUS et  al.,  2009),  which allows them to
penetrate deep into the spinal cord parenchyma and establish infammation.
However,  the  release  of  cytokines  by  infltrating  T cells  may  activate
microglia and also astrocytes, that are beside endothelial cells involved in
maintaining  the  integrity  of  the  BBB,  to  cause  the  release  of  certain
immunomodulators such as chemokines at the pathological site. Tis further
may  compromise  the  BBB,  which  is  becoming  permeable  to  peripheral
immune  cells,  including  lymphocytes  and  myeloid  cells.  As  a  result,  the
infammation is further exacerbated and supports the generation of a chronic
neuroinfammatory disease (TRAN et al., 2000; FLÜGEL et al., 2001; KAWAKAMI
et al., 2004).
1.5 Store-operated calcium entry
As an important intracellular messenger, calcium (Ca2+) exerts functions in
almost  every  cell  type  (BOOTMAN et  al.,  2001).  It  is  involved  in  muscle
contraction, neurotransmiter signaling and synaptic plasticity. In addition to
that, calcium regulates the activity of calcium sensitive enzymes and by that
conducting a wide range of downstream signaling pathways (BERRIDGE et al.,
2000). Te calcium concentration within the cytoplasm is usually low, being
in the range of 100 nM (‘resting state’), which is maintained by ion pumps
that actively export Ca2+ into the extracellular space or sequester Ca2+ into
store organelles frst of all the endoplasmatic reticulum (ER). Upon specifc
stimuli Ca2+ is rapidly released from the ER and enters the cytoplasm through
plasma membrane ion channels (ENDO, 2009). Calcium signaling is initiated
in  many  cell  types  by  activation  of  the  phospholipase  C (PLC)  pathway
(SCHMIDT et al., 2001). Tis particular enzyme can be activated by many cell
surface  receptors,  including  G protein  coupled  receptors  and  tyrosine
kinases.  PLC  catalyses  the  hydrolysis  of  the  membrane  phospholipid
phosphatidylinositol  4,5-bisphosphate  (PIP2)  into  D-myo-inositol  1,4,5-
trisphosphate  (IP3)  and  diacylglycerol  (DAG).  IP3 and  DAG  exert  their
functions  as  second  messengers.  While  DAG  activates  protein  kinase  C
(PKC) and by this several downstream signaling pathways, IP3  binds to ER
membrane bound IP3 receptors (IP3Rs), which are Ca2+ channels itself, leading
to the release of Ca2+ from the ER internal stores. In brief, this Ca2+ efux
activates ‘store-operated channels’ (SOCs) on the plasma membrane which
provokes further  Ca2+ entry from outside the cell.  Tis results  in a  rapid
increase in intracellular Ca2+ to a concentration of 1000 nM (‘activated state’)
(CLAPHAM,  2007).  Te  Ca2+ regulated  enzyme  calmodulin  (‘calcium-
modulated  protein’)  is  one  major  downstream  target  of  store-operated




1.6 Ca2+ signaling in T lymphocytes
Ca2+ ions and their  respective  channels  and transporters  are  essential  for
T lymphocytes in that they regulate cell diferentiation, efector function and
gene transcription (OH-HORA and RAO, 2008).
Fig. 1.1 | Calcium signaling in T lymphocytes. Following formation of the peptide:MHC-
TCR  complex,  PLC  activation  mediates  production  of  second  messenger  IP3 binds  and
activates to ER calcium channels, thereby depleting Ca2+ from the store. This depletion via
STIM1 protein activates CRAC/ORAI channels on the cell membrane and triggers a massive
influx of Ca2+ into the cytosol from extracellular space. As a result, calcineurin phosphatase
becomes activated and induces NFAT translocation into the nucleus by dephosphorylation.
In  the  nucleus  NFAT  mediates  specific  gene  expression.  Ca2+,  calcium  ion;  [Ca2+]i,
intracellular  calcium  concentration;  cADPR,  cyclic  ADP-ribose;  CRAC,  calcium  release
activated  channel;  ER,  endoplasmic  reticulum;  IP3,  inositol-3-phosphate;  IP3R,  inositol-3-
phosphate  receptor;  MHC,  major  histocompatibility  complex;  NAADP,  nicotinic  acid
adenine dinucleotide phophate, NFAT, nuclear factor of activated T cells; ORAI1,  calcium
release-activated  calcium  channel  protein  1;  RyR,  ryanodine  receptor;  STIM1,  stromal
interaction molecule-1; TCR, T cell receptor.
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Stimulation  of  the  T cell  receptor  leads  to  the  activation  of
phospholipase Cγ1 (PLCγ1)  and the  generation of  IP3 (FESKE et  al.,  2012),
which triggers the release of Ca2+ from the ER stores into the cytosol. Tis
sudden release of Ca2+  is sensed by stromal interaction molecule 1 (STIM1)
and STIM2 on the ER membrane, leading to activation of calcium release-
activated  calcium channel  protein  1  (ORAI1),  ORAI2  and ORAI3  that  are
located on the plasma membrane and build the pore of the calcium release-
activated  channel  (CRAC;  FESKE et  al.,  2006).  Te  increase  in  Ca2+
concentration  occurs  within  30–60  seconds  (WÜLFING et  al.,  1998)  and
induces the activation of a series of transcription factors, including cyclic-
AMP-responsive-element-binding protein (CREB), myocyte enhancer factor 2
(MEF2) and nuclear factor of activated T cells (NFAT). NFAT signaling is of
great  signifcance  in  T cells  (MACIAN,  2005;  LODYGIN et  al.,  2013).  Tis
particular transcription factor is  activated by dephosphorylation, which is
carried  out  by  calcineurin,  a  serine/threonine  phosphatase.  Calcineurin
activation is a two-step process. Increase of free cytosolic Ca2+  leads to the
dissociation of the auto-inhibitory domain of calcineurin, which is mediated
by a Ca2+ dependent conformational change of this subunit by that exposing
the  Ca2+/calmodulin  binding  site  of  the  protein.  Binding  of  activated
calmodulin to this site triggers another conformational change of calcineurin
and  full  activation  of  the  enzyme.  Te  dephosphorylated  NFAT  then
translocates  into  the  nucleus  and  induces  transcription  of  T cell
characteristic pro-infammatory cytokines, e.g. IL-2 and IFN-γ (HOGAN et al.,
2003).  In  contrast  to  nuclear  factor-κB (NF-κB),  that  functions  even  at  a
transient increase of Ca2+ concentration, NFAT-dependent gene transcription
requires strong and prolonged intracellular Ca2+  boosts, suggesting multiple
regulatory mechanisms of Ca2+  signaling in T cells (KANNO AND SIEBENLIST,
1996; FESKE et al., 2001; FISCHER et al., 2001). 
1.7 Intracellular Ca2+ release channels
Te  sarcoplasmatic  reticulum  (SR)  and  the  ER  are  the  main  stores  for
intracellular Ca2+ in striated muscle cells or other cell types, respectively. Its
release  is  performed  by  two  major  classes  of  receptors  that  have  been
identifed  on  the  SR/ER  membrane,  termed  IP3 receptors  (IP3Rs)  and
ryanodine receptors (RyRs). A third class of receptors is the target of the
more recently identifed second messenger NAADP (LEE and AARHUS, 1995;
CHURCHILL AND GALIONE, 2000; GALIONE, 2011).
IP3Rs were the frst purifed calcium-induced Ca2+  release (CICR) channels
(SUPATTAPONE et  al.,  1988)  and  hence  studied  intensively  in  their  role  of
converting  external  signals  into  intracellular  Ca2+  responses.  Tey  are
diversely  expressed  and  play  a  role  in  several  cellular  and  physiological
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processes  including  cell  proliferation,  behavior,  memory  and  learning
(BOSANAC et al, 2002). IP3  binding to IP3Rs is essential for Ca2+  release from
the ER (BERRIDGE, 1997). However, IP3Rs are highly regulated ion channels.
Tey  are  modulated  by  phosphorylation,  accessory  proteins,  adenosine
triphosphate (ATP) and, most importantly, Ca2+ itself (GRAFTON and THWAITE,
2001).  Tree isoforms of  IP3Rs are  known, difering in their  sensitivity to
regulation by Ca2+.  Te possibility of the cell  to modulate CICR in such a
distinct manner emphasizes the signifcance of intracellular Ca2+ signaling via
IP3Rs as a ‘spatial-temporal’ event (THOMAS et al., 1996,  YULE, 2001).  Ip3r1-/-
mice are rarely born alive, and adult mice lacking Ip3r1 were sufering from
severe neurological symptoms (MATSUMOTO AND NAGATA, 1999). Experiments
with  bone  marrow  chimeras  show  that  IP3R1  is  dispensable  for  T cell
activation  and  Ca2+  signaling  (HIROTA et  al.,  1998).  Studies  on  mice  with
deletion  of  the  Ip3r2 and/or  Ip3r3 gene  showed  the  importance  of  these
receptors for the generation of Ca2+  signals in astrocytes (SRINIVASAN et al.,
2015).  Te  importance  of  IP3Rs  in  the  context  of  EAE  has  not  yet  been
reported so far.
Besides  IP3,  nicotinic  acid  adenine  dinucleotide  phosphate  (NAADP)  and
cyclic  ADP-ribose  (cADPR)  are  important  second  messengers  for  Ca2+
signaling within T cells (GUSE, 1999; BOOTMAN et al., 2002). Both NAADP and
cADPR are metabolites of nicotinamide adenine dinucleotide (NAD+;  LEE et
al., 1989). Discovered in 1999 by CANCELA et al. in pancreatic cells, NAADP
was observed to trigger Ca2+  release from the ER afer releasing Ca2+  from
much  smaller,  lysosomal  acidic  stores  (CHURCHILL et  al.,  2002).  Tis  is
underlined by the characteristic of NAADP being a rather short-lived second
messenger and it is assumed that it acts before IP3 and cADPR exert their
messaging function (KINNEAR et al., 2004,  KINNEAR et al., 2008,  ERNST et al.,
2013).  It  was demonstrated in Jurkat T cells  that NAADP emerges rapidly
afer stimulation of the TCR/CD3 complex (LEE, 2001; GASSER et al., 2006) and
provides the very frst local Ca2+ signals. Tese signals are thought to ‘prime’
IP3Rs and RyRs before IP3 and cADPR provide amplifying signals for Ca2+
release (GUSE et al., 1995, GALIONE, 2011). Yet, a distinct allocation of NAADP
to a specifc receptor is still under investigation (HOHENEGGER et al.,  2002;
GALIONE, 2011; OGUNBAYO et al., 2011). Even though evidences point out the
family of two-pore channels (TPCs) to be a potential candidate as receptors
for  NAADP (ISHIBASHI et  al.,  2000;  CALCRAFT et  al.,  2009),  data of  human
T cells were presented in that RyRs are required for functional Ca2+ signaling
(LANGHORST et al., 2004), and that in Jurkat T cells RyR1 worked out as the
primary target of NAADP (DAMMERMANN et al., 2009).
cADPR and its  non-cyclic form ADPR are produced from NAD+ by ADP-
ribosyl  cyclases  (PETERSEN AND CANCELA,  1999).  Equally  to  NAADP,  it  is
generated afer  TCR/CD3 ligation (GUSE et  al.,  1995,  GUSE,  1999)  but  acts
directly  on  RyRs  in  Jurkat  T cells  (SCHWARZMANN et  al.,  2002).  Tere,  it
induces  Ca2+  entry  and  makes  RyRs  more  sensitive  to  further  Ca2+  and




Ryanodine receptors (RyRs) are named afer the plant alkaloid ryanodine,
which binds to RyRs with high afnity (IMAGAWA et al., 1987). To our current
knowledge,  RyRs  are  the  largest  known  ion  channels  (TAKESHIMA et  al.,
1989). One receptor consists of four subunits, each approximately 565 kDa in
weight, together forming a homotetramer of about 2.3 MDa (Fig 1.1; ZALK et
al., 2015).
Fig.  1.2 |  3D  structure  of  the  mammalian  RyR1  homotetramer  determined  by
cryoelectronmicroscopy  at  a  resolution  of  4.8 Å.  One  protomer  chain  with  its  diferent
domains is highlighted in color.  Lef panel: View in the plane of the SR membrane.  Right
panel: View from the cytosol. Figures from ZALK et al., 2015.
1.8.1 Ryanodine receptor isoforms
Tree RyR isoforms have been identifed, termed skeletal RyR (RyR1), cardiac
RyR  (RyR2)  and  brain  RyR  (RyR3)  afer  their  major  compartment  of
expression. RyRs are located on the membranes of intracellular Ca2+  stores,
either the SR or the ER and release Ca2+ from those stores upon stimulation.
All  isoforms  of  RyRs  can  be  activated  by  cADPR  and  Ca2+  itself.  While
cADPR is the main agonist for RyRs (LEE, 2001), ERNST et al. (2013) suggest a
possible role of NAADP as a ligand for RyRs in Jurkat T cells. Beside their
major expression compartments, RyRs are also expressed in other cell types
or tissues, repectively, including the immune system. Te expression of RyRs
has been identifed in diferent lymphocyte subsets and some mononuclear
cells (Table 1.1). Of special importance for this thesis was the discovery of
RyR expression in Lewis rat efector T cells (DAMMERMANN et al.,  2009). It
was the frst study on RyR expression in rodent T cells. Tere, expression of
RyRs  is  restricted  to  efector,  in  contrast  to  naïve  or  memory  T cells
(CORDIGLIERI et  al.,  2010).  Furthermore,  it  was  demonstrated  that  certain
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subtypes of RyRs, namely RyR1 and RyR3, but not RyR2 are expressed in rat
efector  T cells,  even though RyR3 was  expressed to  a  lesser  extent  than
RyR1 (DAMMERMANN et al., 2009, CORDIGLIERI et al., 2010).
Table 1.1 | Expression of ryanodine receptor isoforms in immune cells
Cell type RyR1 RyR2 RyR3
Jurkat T cells GUSE et al., 1999 —
HAKAMATA et al.,
1994,
GUSE et al., 1999
CD3+ T cells
(Human)
THAKUR et al., 2012
HOSOI et al., 2001,
THAKUR et al., 2012
THAKUR et al., 2012
CD19+ B cells
(Human)
HOSOI et al., 2001,


















1.8.2 Agonists and antagonists for ryanodine receptors
To unravel the properties of RyRs as intracellular Ca2+  channels, a series of
pharmacological  studies has  been performed,  either with RyR agonists or
antagonists,  respectively.  In  this  context,  the pharmacological  blocking of
RyRs or the initiation of Ca2+  release from the SR/ER was the central aspect
of the studies.
Te alkaloid  ryanodine  is  maybe  the  most  notably  and  most  intensively
studied  ligand  for  RyRs  (Fig.  1.3,  A).  Ryanodine  is  found  in  the  South
American plant  Ryania speciosa and shows high binding afnity to RyRs,
which was used to designate this class of receptors (MEISSNER, 1986, LAI et al.,
1988). It is a highly specifc modulator of RyRs with bilateral properties. At
nanomolar  concentrations,  ryanodine  locks  RyRs  in  their  half-open state,
causing  Ca2+  release,  while  concentrations  in  the  micromolar  range
irreversibly block RyRs and prevent channel opening (LINDSAY et al.,  1994,
TINKER et al.,  1996,  WELCH et al.,  1997). Another RyR blocker is tetracaine
(Fig. 1.3, B), which is used as a local anesthetic (ZUCCHI and RONCA-TESTONI,
1997).  Similar  to  ryanodine,  tetracaine  blocks  RyRs  completely  at  high
concentrations  (>1.25 mM,  GYÖRKE et  al.,  1997)  but  inhibits  Ca2+  release
reversibly at low concentrations (0.25–1.25 mM, OVEREND et al., 1998).
Dantrolene (Fig. 1.3, C) was frst described in 1967 as a muscle relaxant and
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was used to treat malignant hyperthermia (MH), a rare but life-threatening
form of  muscle  dysfunction (SNYDER et  al.,  1967)  that  is  triggered during
treatment  with  general  anesthetics.  In  MH,  patients  are  sufering  from
drastic disorders in skeletal muscle oxidative metabolism, afecting its ability
to  regulate  body  temperature,  to  supply  oxygen  and  to  remove  carbon
dioxide, which may then lead to acidosis, organ failure and eventually, death
(ROSENBERG et al., 2007). MH is an autosomal dominant inherited disease. In
50–70 % of MH patients, mutations have been identifed on the gene coding
for RyR1, that afect its closing mechanism and thereby raising intracellular
Ca2+ levels by excessive Ca2+ mobilization from the SR (GILLARD et al., 1992).
Te disorder is then therapeutically antagonized by dantrolene. Even though
the  mechanism  of  RyR1  inhibition  by  dantrolene  is  not  yet  completely
understood, a direct efect on the RyR1 isoform has been implicated (ZHAO et
al.,  2001,  KOBAYASHI et  al.,  2010).  Furthermore,  it  was  demonstrated  that
dantrolene may act on RyR3 as well, but not on RyR2 (ZHAO et al., 2001). 
Fig.  1.3 |  Skeletal  formulas  of  selected  RyR antagonists  that  block RyR mediated  Ca2+
release. (A) Ryanodine. (B) Tetracain. (C) Dantrolene.
Cafeine (Fig. 1.4, A) was the frst discovered pharmacological substance to
initiate Ca2+ release from intracellular stores via RyRs (ENDO, 1977, ROUSSEAU
et al., 1988). It was shown that cafeine sensitizes RyRs to cytosolic Ca2+  at
low  concentrations  (<1 mM),  while  higher  doses  (>2.5 mM)  increase  the
sensitivity of RyRs to luminal Ca2+ (LEE, 1993, PORTA et al., 2011).
Te ability of cyclic ADP-ribose (cADPR, Fig. 1.4, B), a metabolite of NAD+,
to stimulate Ca2+  release via RyRs in sea urchin egg microsomes has been
reported  (GALIONE,  1993,  GALIONE,  1994).  Tese  reports  could  be  further
extended to smooth muscle cells (MURTHY et al., 1995, PRAKASH et al., 1998)





cADPR can induce Ca2+ signaling independently from IP3 (DARGIE et al., 1990),
and acting instead via the potentiation of CICR (GALIONE et al.,  1991,  LEE,
1993). Te mechanism of cADPR is similar to that of cafeine, however, it
shows higher potency in sensitization of RyRs to Ca2+. It has been suggested
that  interplay between cADPR and calmodulin as an accessory protein is
essential for RyR activation in sea urchin eggs (LEE et al.,  1994,  LEE et al.,
1995, TANAKA and TASHJIAN, 1995). Tere, cADPR induces a short, but rapid
Ca2+  release, which is sustained by calmodulin. By means of single-particle
electron  cryomicroscopy,  a  calmodulin-like  domain  within  the  core  of
mammalian  RyR1  was  identifed  as  a  calcium sensor  (ZALK et  al.,  2015),
thereby  confrming  previous  results  suggesting  calmodulin  directly
interacting with RyR1 (XIONG et al., 2006). 
Fig. 1.4 | Skeletal formulas of selected RyR agonists that initiate RyR mediated Ca 2+ release.
(A) Cafeine. (B) cADPR. (C) NAADP.
Such as cADPR, NAADP (Fig. 1.4, C) is a metabolite of NAD+. It was long
assumed that NAADP—in contrast to cADPR and IP3—mobilizes Ca2+  from
separable  stores  (LEE and  AARHUS,  1995),  namely  acidic  lysosomes
(CHURCHILL et  al.,  2002).  However,  it  was demonstrated that NAADP is  a
potent mobilizer for Ca2+  in Jurkat T cells (BERG et al.,  2000) and mediates
T cell  activation by high-afnity binding to RyRs (LANGHORST et al.,  2004,
DAMMERMANN and  GUSE,  2005).  Furthermore, it  could be shown in both—





T cells—that NAADP signaling to RyR1 could be successfully suppressed by
BZ194, a synthetic NAADP antagonist (DAMMERMANN et al., 2009), showing
that NAADP is an efective agonist for RyR1. Tereby the antagonizing efect
of BZ194 was exclusively afecting the NAADP signaling pathway, but not
cADPR or IP3 mediated Ca2+ signaling (DAMMERMANN et al., 2009). Preventive
or therapeutic treatment of Lewis rats with BZ194 signifcantly ameliorated
the course of EAE but did not afect primary immune responses (CORDIGLIERI
et al., 2010). Accordingly, NAADP signaling is essential for the activation of
auto-aggressive T cells.
1.9 Objectives of this study
RyRs  are  a  family  of  Ca2+ channels  that  mediate  Ca2+  release  from
intracellular  stores  upon  activation  by  secondary  messengers,  such  as
NAADP or  cADPR.  In  non-excitable  cells,  the  depletion  of  Ca2+  stores  in
response  to  external  stimuli  evokes  further  Ca2+entry  across  the  plasma
membrane,  thereby  activating  Ca2+  sensitive  signaling  pathways.  For
example,  the  increase  of  intracellular  Ca2+  in  T cells  represents  an  initial
trigger for TCR dependent T cell activation.
T cells play a pivotal role in autoimmune diseases of the CNS like MS and its
animal model EAE. Te understanding of intrinsic factors that control the
activation of (auto-aggressive) T cells is indispensable for the development of
new therapies. In this context, the role of RyRs has been poorly investigated.
However,  recent  studies  suggested  RyRs  as  a  therapeutic  target  in  T cell
mediated autoimmune diseases.
Using Ryr1 and Ryr3 knockout mice, we aim to address following point:
1. Analysis of a steady state immune system in mice with ablation of the
RyR1 and RyR3 genes.
2. Efect  of  RyR1 or  RyR3 deletion on the clinical  outcome and CNS
pathology of active EAE.
3. Determination  of  mechanisms  that  mediate  RyR1  and  RyR3
contribution to the autoimmune neuroinfammatory disease.
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2 Materials and Methods
2.1 Bufers and Media
All  solutions  were  prepared  in  Milli-Q  purifed  water  (MERCK MILLIPORE,
Schwalbach, Germany) and sterilized by autoclaving and / or fltration before
use. If not declared otherwise, all chemicals were purchased from CARL ROTH
(Karlsruhe, Germany) or SIGMA-ALDRICH (Munich, Germany).
Ammonium-Chloride-Potassium (ACK) erythrolysis bufer
0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM EDTA·2Na in H2O, pH 7.2–7.4.
Dulbeccos’s Modifed Eagle Medium (DMEM)
133.8 g  Gibco® DMEM  powder  (LIFE TECHNOLOGIES,  Carlsbad,  California,
USA) in 10 L H2O, supplemented with 37 g acetic acid (CH3COOH).
Eagle’s HEPES (EH) medium
133.8 g  Gibco® DMEM  powder  (LIFE TECHNOLOGIES,  Carlsbad,  California,
USA) in 10 L H2O, supplemented with 37 g CH3COOH and 25 mM HEPES
(LIFE TECHNOLOGIES).
FACS bufer
1×PBS supplemented with 0.5 % BSA and 0.05 % NaN3.
Glial cell medium (GCM)
GCM was prepared by supplementing DMEM with 15 % FCS (BIOCHROM AG,
Berlin,  Germany),  1 %  Gibco® minimum  essential  medium  non-essential
amino  acids  (MEM  NEAA,  100x,   LIFE TECHNOLOGIES), 1 %  Gibco®
penicillin/streptomycin  (10,000 units/ml  penicillin,  10,000 µg/ml
streptomycin,  LIFE TECHNOLOGIES),  1 mM  Gibco® sodium  pyruvate
(LIFE TECHNOLOGIES), 2 mM  L-glutamine  (PAN-BIOTECH,  Aidenbach,




L929 fbroblast-conditioned medium (LCCM)
L929 cells were plated in a 10 cm petri dish (SARSTEDT, Nümbrecht, Germany)
with  DMEM  supplemented  with  10 %  FCS  and  1 %  Gibco®
penicillin/streptomycin,  1 mM  Gibco® sodium  pyruvate  and  2 mM
L-glutamine. Confuent cells were splited into 175 cm2 fasks. Afer reaching
confuence,  the  supernatant  was  collected  and  passed  through  a  0.22 µM
flter. Te obtained medium was stored as 5×LCCM.
Percoll, isotonic Percoll and underlay Percoll solutions
Percoll® (GE  HEALTHCARE,  Chalfont  St.  Giles,  UK)  density  centrifugation
medium was diluted 1:10 with 10×PBS to produce isotonic Percoll. Underlay
Percoll was composed of 70 % isotonic Percoll in 1×PBS.
Phosphate bufered saline (PBS)
137 mM NaCl,  2.7 mM KCl,  10 mM Na2HPO4 and 1.8 mM KH2PO4 in H2O,
pH 7.4. Ten times the amount of NaCl, KCl, Na2HPO4 and KH2PO4 was used
to produce 10×PBS.
Proteinase K bufer
100 mM Tris·HCl, 200 mM NaCl, 0.2 % SDS and 5 mM EDTA in H2O, pH 8.0.
Fresh  Proteinase K  (10 mg/ml)  was  added  directly  before  use  to  a  fnal
concentration of 1 %.
Roswell Park Memorial Institute medium 1640 (RPMI 1640)
104.3 g  Gibco® RPMI  1640  powder  (LIFE TECHNOLOGIES) in  10 L  H2O,
supplemented with 22 g NaHCO3.
Restimulation medium (ReMed)
ReMed was prepared by supplementing RPMI 1640 with 5 % FCS, 1 % Gibco®
minimum essential medium non-essential amino acids (MEM NEAA, 100×,
LIFE TECHNOLOGIES), 1 %  Gibco® penicillin/streptomycin  (10,000 units/ml
penicillin,  10,000 µg/ml  streptomycin,  LIFE TECHNOLOGIES),  1 mM  Gibco®
sodium  pyruvate  (LIFE TECHNOLOGIES), 2 mM  L-glutamine  (PAN-BIOTECH,
Aidenbach, Germany) and 0.4 % 2-mercaptoethanol (13.6 M).
Tris/Borate/EDTA (TBE) bufer, 10×




2.2.1 Genotyping by polymerase chain reaction (PCR)
Genomic DNA (gDNA) was obtained by isopropyl alcohol precipitation afer
digestion  of  tissue  or  cells  with  Proteinase  K  (2–16 h,  56 °,  dry  block
thermostat TDB-100, BIOSAN). DNA fragments were amplifed by PCR using
the DreamTaq Polymerase Mix (THERMO FISCHER SCIENTIFIC INC.,  Waltham,
Massachusets,  USA) and  target  specifc  primer  pairs  (BIOMERS,  Ulm,
Germany).  Amplifcation  programs  were  specifc  for  each  set  of  primers
(Mastercycler ep gradient, EPPENDORF, Hamburg, Germany).
PCR  products  were  loaded  on  0.8–1.5 %  TBE  agarose  gels  and
electrophoresed at 100 V for 30–60 min before visualization with an E-BOX
VX5  gel  documentation  system  and  the  corresponding  VisionCapt  15.0
sofware (VILBER LOURMAT, Eberhardzell, Germany).
Table 2.1 | Primers for sequencing
Primer Sequence
Ryr1-KO fwd TGG CCT GTC CCT TCT GGT TCC CAC C
Ryr1-KO rev CCC TTT CCC CTA TTA GCC GAT CAC T
Ryr3-KO fwd ATG AAG TTG TAC TCC AG TGC ATT GC
Ryr3-KO rev TCC AGG AAT CTC TGG TAT ACT AGG G
NeoR fwd GAA TAT CAT GGT GGA AAA TGG CCG CTT TTC
2.2.2 RNA extraction and cDNA synthesis
Te RNeasy Kit (QIAGEN,  Hilden, Germany) was used to isolate RNA from
either  organs,  tissues  or  cells.  Obtained RNA was transcribed into cDNA
using random hexamer primers (FirstStrand cDNA Synthesis Kit,  THERMO
FISCHER SCIENTIFIC INC.) according to the manufacturer’s instructions. cDNA
was either stored at -20 ° or subsequently used as template for quantitative
real-time PCR.
2.2.3 Qantitative real-time polymerase chain reaction
Gene expression was assessed by (semi-) quantitative real-time PCR (qPCR)
using  the  StepOnePlus™ Real-Time  PCR  System  (APPLIED BIOSYSTEMS,
Darmstadt,  Germany)  and  the  corresponding  StepOne  Sofware  v2.0.  Te
qPCR  was  performed  with  gene-specifc  TaqMan® probes  labeled  with
6-FAM™ and quenched by TAMRA™. β-actin was used as the housekeeping
gene. Individually designed primers and probes were ordered from  SIGMA-
17
Materials and Methods
ALDRICH.  Before  applied in qPCR,  cDNA samples  were diluted 1:50.  Data
from samples were obtained in duplicates.
Primer and probe sequences for qPCR: Actb, sense, 5´-GTA CAA CCT CCT
TGC AGC TCC T-3´; antisense, 5´-TTG TCG ACG ACG AGC GC-3´; probe,
5´-[6FAM]-CGC CAC CAG TTC GCC ATG GAT-[TAMRA]-3´.  Ccl2, sense,
5´-TGT CAT GCT TCT GGG CCT GC-3´; antisense, 5´-CCT GCT GCT GGT
GAT CCT CT-3´;  probe,  5´-[6FAM]-CTC ACC TGC TGG TAC TCA TTC
ACC-[TAMRA]-3´.  Ccl5,  sense,  5´-GGA GTA TTT  CTA CAC  CAG CAG
CAA-3´; antisense,  5´-CAC  ACA  CTT  GGC  GGT  TCC  TT-3´;  probe,  5´-
[6FAM]-TGC  TCC  AAT  CTT GCA GTC GTG TTT  GTC  A-[TAMRA]-3´.
Ccr5, sense, 5´-GTT CTC CTG TGG ACC GGG TAT ACG-3´; antisense, 5´-
ATT GTC AAA CGC TTC TGC AAA C-3´; probe, 5´-[6FAM]-AGC TTA CAC
GAT CAG GAT T-[TAMRA]-3´.  Ccr6, sense, 5´-TCG TCC AGG CAA CCA
AAT C-3´;  antisense,  5´-CCA CAC TGC CAC ACA GAT  GAC-3´;  probe,
[6FAM]-TTC CGG GTA CGC TCC AGA ACA CTG A-[TAMRA]-3´.  Ccr7,
sense, 5´-GTG TAG TCC ACG GTG GTG TTC TC-3´; antisense, 5´-CTG GTC
ATT TTC CAG GTG TGC T-3´; probe, 5´-[6FAM]-CCG ATG TAG TCG TCT
GTG A-[TAMRA]-3´.  Csf2,  sense,  5´-GGG CGC CTT GAA CAT GAC-3´;
antisense,  5´-CGC  ATA  GGT  GGT  AAC  TTG  TGT  TTC-3´;  probe,  5´-
[6FAM]-CCC CCC AAC TCC GGA AAC GGA-[TAMRA]-3´. Cxcl10, sense, 5
´-CAT CCC TGC GAG CCT ATC C-3´; antisense, 5´-CAT CTC TGC TCA
TCA TTC TTT TTC A-3´; probe, 5´-[6FAM]-CCC ACG TGT TGA GAT CAT
TGC CAC G-[TAMRA]-3´. Cxcr3, sense, 5´-AGC AGC CAA GCC ATG TAC
CTT-3´; antisense, 5´-TAG GGA GAT GTG CTG TTT TCC A-3´; probe, 5´-
[6FAM]-AGG TCA GTG AAC GTC AAG GTC TAG ATG CCT C-[TAMRA]-3
´. Cxcr4, sense, 5´-GAG GTC ATC AAG CAA GGA ATG T-3´; antisense, 5´-
GGG TTC AGG CAA CAT TGG A-3´; probe, 5´-[6FAM]-TTC GAG AGC GTC
GTG CAC AA-[TAMRA]-3´.  Icam1,  sense,  5´-GCC AAG CCC ACG CTA
CCT-3´; antisense, 5´-TCT CTG GGA TGG ATG GAT ACC T-3´; probe, 5´-
[6FAM]-TCA  CCG  TTG  TGA  TCC  CTG  GGC  CT-[TAMRA]-3´.  Vcam1,
sense, 5´-CAG AGT GTA CAG CCT CTT TAT GTC AAC-3´; antisense, 5´-
GGA CTG CCC TCC TCT AGT ATA GGA-3´; probe, 5´-[6FAM]-TTG CCC
CCA AGG AAA CCA CCA TC-[TAMRA]-3´. Ifng, sense, 5´-TCA AGT GGC
ATA GAT GTG GAA GAA-3´; antisense, 5´-TGG CTC TGC AGG ATT TTC
ATG-3´; probe, 5´-[6FAM]-TCA CCA TCC TTT TGC CAG TTC CTC CAG-
[TAMRA]-3´. Ryr1, sense, 5´-CCG CCC TCA GGT TCC CCG CCA AGC C-3
´; antisense, 5´-GCG GTG CCG AAC CCC TCA GCG G-3´; probe, 5´-[6FAM]-
ATG GAG GAG GTG AAG GCG AG-[TAMRA]-3´. Ryr3, sense, 5´ATG AAG
TTG TAC TCC AGT GCA TT-3´; antisense, 5´-CAC GAA ATT GCA GAC
ACA GAG ATC-3´; probe, 5´-[6FAM]-GCA GCC GAG GGA CTT GGG AA-
[TAMRA]-3´.  Tnfa,  sense,  5´-TCG  AGT  GAC  AAG  CCC  GTA  GC-3´;
antisense, 5´-CTC AGC CAC TCC AGC TCC TC-3´; probe, 5´-[6FAM]-CGT
CGT AGC AAA CCA CCA AGC AGA-[TAMRA]-3´.
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2.3 Cell Culture Procedures
If not declared otherwise, cells were incubated at 37 ° in a humidifed 5 %
CO2 atmosphere.
2.3.1 Preparation of cell suspensions from organs
Single  cell  suspensions  of  lymph  nodes  and  spleen  were  prepared  by
smashing  the  organs  through  a  metal  mesh  (UNIVERSITÄTSMEDIZIN
GÖTTINGEN,  in-house production) using a pistil (B. BRAUN MELSUNGEN AG,
Melsungen,  Germany).  Te  obtained  homogenizate  was  centrifuged  (4 °,
1200 rpm, 5 min) and resuspended in EH medium.
2.3.2 Erythrolysis
Erythrocytes residing in spleen or blood were depleted by resuspension of
spleen homogenates or blood samples in ACK bufer and further incubation
for 5 min on ice. Ten, the cells were washed once in PBS and resuspended in
EH medium.
2.3.3 Lymphocyte isolation from blood
Blood was either collected from the tail vein (living animals) or by cardiac
puncture (dead animals) in 80 mM EDTA/PBS. Lymphocytes were separated
from whole blood by the use of lymphocyte separation medium 1077 (LSM
1077,  GE  HEALTHCARE,  Chalfont  St.  Giles,  UK)  and  centrifugation  at
2000 rpm  for  20 min  at  4 °  with  minimal  acceleration  and  brakes.
Lymphocytes  accumulated  at  the  interphase  and  were  collected  in  FACS
bufer.
2.3.4 Lymphocyte isolation from CNS
Lymphocytes  were  isolated  from  spinal  cord  or  brain  by  Percoll  density
gradient centrifugation. Te CNS tissue was minced into a fne slurry, taken
up in 25 ml EH medium and then mixed with 10 ml of isotonic Percoll. 10 ml
of underlay Percoll medium was pipeted gently under the cell suspension
prior to centrifugation (20 °, 30 min, 2780 rpm) with minimal acceleration
and brakes.
2.3.5 Isolation and enrichment of T and B cells
Single cell suspensions of lymph nodes or spleen were prepared as described.
For  the  isolation,  a  concentration  of  1 × 108 cells/ml  was  achieved  in
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recommended resuspension medium.  CD3+ T cells, naïve T cells and B cells
were isolated using the EasySep™ Enrichment Kits for murine CD3+ T cells,
naïve CD4+ T cells and B cells (each  STEMCELL TECHNOLOGIES, Vancouver,
British Columbia, Canada) according to the manufacturer’s instructions for
“Te Big Easy” EasySep™ Magnet. In brief, biotinylated antibodies directed
against  non-wanted  cell  populations  and  tetrameric  antibody  complexes
against  biotin  conjugated  with  dextran-coated  magnetic  particles  were
applied  to  the  single  cell  suspension  to  mark  cells  for  magnetic  forced
removal. Afer enrichment, the cell purity was determined by fow cytometry
and was usually ≥90 %.
2.3.6 Isolation of astrocytes via MACS® purifcation
Astrocytes  from spinal  cord  were  isolated  using  the  MACS® anti-GLAST
MicroBead Kit (MILTENYI BIOTECH GMBH, Bergisch Gladbach, Germany).
2.3.7 Generation of primary astrocytes and microglia
Cell  cultures  of  primary  astrocytes  and  microglia  were  generated  as
described (CHEN et  al.,  2012).  In brief,  neonatal  mice (age 0–2 days)  were
killed by decapitation. Te skin over the skull was fayed before opening the
skull  itself  to access the brain. Te brain was then placed on ice and the
meninges were removed using a Stemi 2000 stereo microscope (CARL ZEISS,
Jena,  Germany).  Te  cleaned  brain  was  minced  into  a  fne  slurry  and
aferward digested with trypsin/EDTA for 15–30 min in a 37 ° incubator.
Te suspension was passed through a Falcon® 40 µm cell strainer (CORNING,
INC.,  Corning,  New  York,  USA),  centrifuged  (4 °,  1200 rpm,  5 min),
resuspended in glial cell medium (GCM) and added to poly-D-lysine coated
tissue  culture  fasks  (TPP  TECHNO PLASTIC PRODUCTS AG,  Trasadingen,
Switzerland).  Te  cells  were  incubated  at  37 °  in  a  humidifed  5 %  CO2
atmosphere for 24 h before adding LCCM. Afer 10–14 days the microglial
cells  were  detached  by  using  a  heated  orbital  shaker  (INKUTEC GMBH,
Kiebitzhörn,  Germany)  at  240 rpm for  2 h.  Both  microglia  and remaining
plate-bound  astrocytes  could  be  further  cultured  in  GCM  at  37 °  in  a
humidifed 5 % incubator. Cell purity was assessed by immunocytochemistry.
2.3.8 Cell counting
To determine the cell number within a certain volume, 10 µl of a given cell
suspension  were  loaded  on  a  Neubauer  improved  hemocytometer  (LO
LABOROPTIK LTD,  Lancing,  UK).  Trypan  blue  (0.04 %)  was  added  to  the
suspension  to  distinguish  between  viable  and  non-viable  cells.  Te  cell








All animal experiments were carried out in the central animal facility of the
University Clinical School Götingen in accordance with the regulations for
animal welfare of Lower Saxony, Germany. All mouse strains were kept in
individually  ventilated  cages  under  specifc-pathogen-free  conditions  in  a
normal 12 h day-night cycle and fed ad libitum. Experiments were performed
with at least 10 weeks old mice. Te following C57BL/6 strains were used:
Wildtype  (WT,  CHARLES RIVER LABORATORIES,  Wilmington,  Massachusets,
USA), WT, CD45.1 congenic (CHARLES RIVER LABORATORIES), TCRMOG (2D2,
BETELLI et al., 2003), IgHMOG (T, LITZENBURGER et al., 1998), OT II (BARNDEN
et  al.,  1998),  Rosa26-tdRFP  (LUCHE et al.,  2007),  Ryr1+/- (TAKESHIMA et al.,
1994),  Ryr3-/- (TAKESHIMA et al., 1996). We crossed these strains to generate
the following mutants that were used for this study: Ryr1+/-×RFP, Ryr3-/-×RFP,
Ryr1+/-×Ryr3-/-×RFP,  Ryr3-/-×2D2×RFP,  Ryr3-/-×2D2×IgHMOG×RFP,  Ryr3-/-
×OT II×RFP.
2.4.2 Generation of fetal liver and bone marrow chimeric mice
In brief, pregnant female donor mice were euthanized at gestation day 14.
Te  individual  embryos  were  removed  aseptically  and  fetal  livers  were
isolated. A single-cell suspension was made by passing the liver through a
1 ml  pipete  tip.  Afer  centrifugation  the  cells  were  resuspended  in
StemSpan™ medium supplemented with 20 ng/ml  SCF,  20 ng/ml  IL-3  and
50 ng/ml  IL-6  (STEMCELL TECHNOLOGIES SARL,  Cologne,  Germany)  and
cultivated  for  3–4 h.  About  5 × 106 cells  were  intravenously  injected  into
lethally  irradiated  mice  (C57Bl/6:  12.5 Gy).  Recipient  animals  were
maintained on neomycin trisulfate (2 mg/ml) containing drinking water for
4 weeks to prevent infections.
To generate bone marrow chimeric mice, donor mice were euthanized and
the femur and tibia were collected. Afer removing excess fesh and the ends
of the bone the bone marrow was fushed out using a 27-gauge needle. Afer
erythrolysis, cells were counted and about 7 × 106 cells  were injected into
lethally  irradiated  mice  (C57Bl/6:  12.5 Gy).  Recipient  animals  were
maintained on neomycin trisulfate (2 mg/ml) containing drinking water for
4 weeks to prevent infections.
Afer 4 weeks, peripheral blood was collected to screen recipient mice for




2.4.3 MOG35-55 EAE induction by active immunization and disease  
evaluation
Mice  were  anesthetized  by  injection  of  ketamine  (80 mg/kg,  MEDISTAR,
Ascheberg,  Germany)  and  xylazine  (8 mg/ml,  ECUPHAR, Greifswald,
Germany).  EAE  was  then  induced  by  immunization  with  the  2D2  TCR
epitope  MOG35-55 (MEVGWYRSPFSRVVHLYRNGK,  purchased  from  the
Institute  for  Medical  Immunology,  CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN,
Germany) in at least 10 weeks old mice. Antigen emulsion containing 50 µg
complete Freund’s adjuvant (incomplete Freunds’s adjuvant (Difco™, BECTON
DICKINSON,  Franklin  Lakes,  New  York,  USA,  supplemented  with
Mycobacterium tuberculosis H37Ra (Difco™,  BECTON DICKINSON)) and 50 µg
MOG35-55 was injected subcutaneously at the base of the tail. Pertussis toxin
(LIST BIOLOGICAL LABORATORIES,  Campbell,  California,  USA)  was  injected
intraperitoneal on the day of immunization and 48 h later (except fetal liver
and  bone  marrow  chimeras).  Te  mice  were  weighed  and  examined  for
clinical signs of EAE daily, starting on day 7 afer immunization. EAE was
assessed according to the following scoring system:
Score 0: healthy; no motor defcits and full tail tone;
Score 1: reduced tail tone;
Score 2: faccid tail paralysis;
Score 3: absent body righting when walking;
Score 4: gait ataxia;
Score 5: mild paralysis of hind limbs;
Score 6: paralysis of one hind limb or moderate hind limb paraparesis;
Score 7: severe paraparesis or paraplegia;
Score 8: tetraparesis;
Score 9: moribund state;
Score 10: dead.
Mice with a score of ≥5 were provided with easier access to food and water.
For ethical reasons, mice with a score ≥7 were sacrifced.
2.4.4 Dantrolene injections
Dantrolene sodium salt was solved in 10 % DMSO in PBS and was injected
daily intraperitoneally at a concentration of 20 mg/kg body weight.
2.4.5 Euthanasia




2.5.1 Staining of cell surface markers
Surface proteins were stained with fuorescently labeled antibodies. 1 × 106
cells  were  resuspended  in  200 µl  FACS  bufer  containing  the  respective
antibodies  and  incubated  in  the  dark  at  4 °  for  30 min.  Cells  were
centrifuged at 4 ° at 1200 rpm for 5 min before transfer into 5 ml FACS tubes
(BD BIOSCIENCES,  Franklin Lakes,  New Jersey, USA) in a volume of 200 µl
FACS bufer.
2.5.2 Flow cytometry
FACS  analysis  was  performed  using  the  fow  cytometer  FACSCalibur™
(BD Biosciences), that consists of an air-cooled argon laser (λex=488 nm) and
a red diode laser (λex=640 nm), enabling the measurement of four diferent
fuorescent parameters (channels).
With a fow cytometer the cell number in a given sample could be quantifed
using Calibrite APC beads (BD BIOSCIENCES). A certain number of beads was
resuspended in PBS and 50 µl  of  the suspension was added to 200 µl  cell
suspension. Te total cell number was calculated as follows:
(Beads /50 µl×Acquired CellsAcquired Beads )×Dilution Factor=Cell Count
Table 2.2 | Antibodies used for flow cytometry
Antigen Label Clone Company
CD4 APC RM4-5 BIOLEGEND
(San Diego, California, USA)
PE-Cy5 H129.19 BIOLEGEND
CD8a biotin 53-6.7 BD PHARMINGEN™
(Franklin Lakes, New Jersey, USA)
FITC 53-6.7 BD PHARMINGEN™
CD25 APC 3C7 BIOLEGEND
FITC 3C7 BIOLEGEND
CD44 APC IM7 BD PHARMINGEN™
FITC HI44a IMMUNOTOOLS
(Friesoythe, Germany)
CD45.1 Biotin A20 BIOLEGEND
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CD45R/B220 APC RA3-6B2 BIOLEGEND
CD62L biotin MEL-14 BD PHARMINGEN™
FITC MEL-14 BIOLEGEND
CD69 FITC H1.2F3 BIOLEGEND
MHC-II (I-Ab) APC AF6-120.1 BIOLEGEND
Streptavidin FITC, PE-Cy5 — BIOLEGEND
TCR β chain FITC H57-597 BIOLEGEND
2.5.3 CFSE dilution assay
Isolated,  antigen-specifc  T cells  were  labeled  with  carboxyfuorescein
diacetate succinimidyl ester (CFSE). In brief, 2 × 106 T cells were incubated in
the presence of 0.25 µM CFSE for 10 min at 37 °. Te CFSE labeled cells were
then injected i.v. into host animals. 48 h hours afer transfer the mice were
immunized with MOG35-55. T cell proliferation in draining lymph nodes, non-
draining lymph nodes and spleen was determined 48 h, 60 h, 72 h and 96 h
afer immunization by measuring the dilution of CFSE occurring with every
cell division using fow cytometry.
2.5.4 Transwell migration assay
T cells  were  activated  in  vivo by  immunization  of  mice  against  MOG35-55
peptide.  On  day 9  afer  immunization,  lymph  nodes,  spleen  and  blood
samples were taken and T cells were isolated by negative selection. Te cells
were then labeled with 0.25 µM CFSE and placed on the upper layer of the
cell  permeable  membrane  (pore  size  5.0 µm)  of  the  migration  chamber
(Boyden multiwell chamber,  CORNING INC., New York, USA), allowing them
to migrate towards the lower chamber which contains the testing solution.
Te quantity of migrated cells was assessed by FACS afer 5 h of incubation.
2.5.5 Glutamate release detection assay
Te concentration of free glutamate in astrocyte culture supernatants was
assessed  by  using the  Glutamate  Colorimetric  Assay  Kit  (BIOVISION,  INC.,
Milpitas,  California,  USA)  according  to  the  manufacturer’s  instructions.
Confuent  grown  cultures  of  astrocytes  were  stimulated  as  indicated.
Supernatants were collected 10 min, 2 h and 16 h afer stimulation and were
diluted 1:10 before use.
24
Materials and Methods
2.5.6 Tymidine incorporation assay
Lymphocytes,  splenocytes  or  enriched  T  cells  (3 × 105/well,  in  triplicates)
were stimulated with indicated concentrations of anti-CD3 and/or anti-CD28
antibodies,  or  MOG35-55 peptide in  ReMed  (37 °,  5 %  CO2).  Afer  24 h  of
stimulation,  tritiated thymidine ([3H]dT, 2 Ci/mmol,  GE HEALTHCARE)  was
added  to  the  culture.  Radioactivity  was  measured  16 h  later  using  a
MicroBeta Trilux 1450LSC β counter (PERKINELMER, Waltham, Massachusets,
USA).
Table 2.3 | Antibodies used for culture assays (for T cell stimulation)
Antigen Host Clone Company
CD3 Rat 145-2C11 BIOLEGEND
CD28 Rat 37.51 BIOLEGEND
2.6 Immunocytochemistry
2.6.1 Cytospin and staining of suspension cells
For fuorescent stainings of non-adhering cells, 5–10 × 104 cells were gently
spun  down  (1000 rpm,  7 min,  medium  acceleration  and  brakes,  RT)  on
Superfrost™ Plus  microscope  slides  using  a  Cytospin® 4  cytocentrifuge
(THERMO FISCHER SCIENTIFIC INC.).  Te cells were then frst fxed with 4 %
PFA for 15 min before blocking in 10 % FCS / 0.02 % Triton X-100 in PBS for
30 min  at  RT  in  a  humidifed  chamber  to  prevent  drying  of  cells.  Ten,
primary  antibodies  were  applied  O/N  at  4 °  in  blocking  bufer.  Afer
washing  with  PBS,  secondary  antibodies  were  applied  for  60 min  at  RT.
Aferward, nucleic acids were stained with DAPI (5 min, RT) to visualize cell
nuclei.  Te  samples  were  mounted  with  one  drop  of  Fluoromount-G™
(SOUTHERNBIOTECH,  Birmingham,  Alabama,  USA)  and  sealed  with  a
coverslip. Te slides were then directly used for microscopy or stored in the
dark at 4 °.
2.6.2 Staining of adherent cells
To stain adherent cells like astrocytes and microglia, the cells were detached
by trypsinization and seeded on cleaned coverslips in a 6-well  or 12-well
plate. Afer 24 h, the cells were fxed with 4 % PFA for 15 min before blocking
in  10 %  FCS  /  0.02 %  Triton  X-100  in  PBS  for  30 min  at  RT.  Ten  the
coverslips were taken out and further processed upside down on Paraflm
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slices  (BEMIS COMPANY,  INC.,  Neenah,  Wisconsin,  USA)  to  allow  lower
incubation  volumes  for  the  antibody  solutions.  Afer  incubation  with
primary and secondary antibodies and DAPI (as described in chapter 2.6.1),
the coverslips were mounted with one drop of Fluoromount-G™ and placed
upside down on a microscope slide before microscopy or storage.
Table 2.4 | Primary antibodies used in immunocytochemistry
Antigen Dilution Host Clonality Company
RyR1 1:1000 Rabbit Polyclonal MILLIPORE
RyR3 1:1000 Rabbit Polyclonal MILLIPORE
GFAP 1:1000 Rabbit Polyclonal DAKO
(Glostrup, Denmark)
1:200 Mouse Monoclonal BIOLEGEND
Iba1 1:1000 Rabbit Polyclonal WAKO PURE CHEMICALS 
INDUSTIRES, LTD. (Neuss, Germany)
Table 2.5 | Secondary antibodies used in immunocytochemistry
Antigen Dilution Host Label Company
Rabbit IgG 1:500 goat Cy-2 MILLIPORE
1:500 goat AF-594 ABCAM
Mouse IgG 1:500 rat FITC BD PHARMINGEN™
2.6.3 Image acquisition
Fluorescent  images  were  acquired  using  the  Zeiss  Axio  Observer.Z1
microscope equipped with a Zeiss Plan Apochromat 20× or 40× lens (both
CARL ZEISS,  Jena,  Germany)  and  a  HXP  120C  metal  halide  lamp
(LEISTUNGSELEKTRONIK JENA  GMBH,  Jena,  Germany)  as  a  light  source.
Fluorescent emission was detected using a Zeiss AxioCam HSm (CARL ZEISS).
Excitation (λex) and emission(λem) wavelengths were as followed: GFP, FITC,
λex=470 nm,  λem=509 nm;  RFP,  AF594,  λex=558 nm;  λem=583 nm;  DAPI,
λex=350 nm;  λem=470 nm.  Images  were  processed  by  using  the  Zeiss
AxioVision v4.8 sofware (CARL ZEISS).
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2.7 Histology and Immunohistochemistry
2.7.1 Perfusion
Afer euthanasia, the thorax was opened to access the heart. Te mice were
frst perfused with PBS through the lef ventricle for  10 min and a small
incision was made into the right atrium to allow efux of the blood. Te mice
were then perfused for another 10 min with 4 % PFA to allow fxation of
tissues. Afer perfusion, organs of interest were stored in 4 % PFA for at least
another 48 h at 4 ° before further processing.
2.7.2 Dehydration and parafn embedding of fxed tissues
PFA-fxed organs were washed with PBS and sliced into appropriate pieces
before inserting them into tissue cassetes (TESPA,  Gießen, Germany).  Te
samples were then dehydrated (70 % EtOH, 1 change, 60 min; 80 % EtOH, 1
change, 60 min; 90 % EtOH, 2 changes, 60 min each; 95 % EtOH, 2 changes,
90 min each; 100 % EtOH, 2 changes, 90 min each; xylene, 2 changes, 60 min
each;  parafn  wax,  56–58 °,  120 min  each)  with  an  automatic  tissue
processor  TP1020  (LEICA BIOSYSTEMS,  Wetzlar,  Germany).  Following
dehydration, tissues were embedded into parafn blocks with a Leica EG1160
embedding machine.
2.7.3 Preparation of embedded samples for tissue stains
Te tissue containing parafn blocks were cut into 3 µm thick slices with a
Leica SM2000R microtom, taken up on microscope slides and dried at 37 °
O/N.  Prior  to  further  processing,  samples  were  rehydrated  (xylene,  2
changes,  15 min each;  100 %  EtOH,  2  changes,  2 min each;  96 %  EtOH,  2
changes,  2 min each;  70 % EtOH, 2 changes,  2 min each;  distilled water,  2
changes, 2 min).
2.7.4 Hemalum & eosine (HE) stain
Rehydrated samples were stained with fltered Mayer’s hemalum solution
(MERCK,  Darmstadt,  Germany)  for  10 min to visualize  nuclei,  followed by
10 min extensive washing with non-distilled water. To stain the cytoplasm,
the samples were exposed to 0.1 % eosine Y solution (MERCK,  diluted with
acetic  acid)  for 2 min. Afer washing,  the samples were again dehydrated
(70 % EtOH, 2 changes, 2 min each; 96 % EtOH, 2 changes, 2 min each; 100 %
EtOH, 2 changes, 2 min each; xylene, 2 changes, 15 min each), mounted with
Entellan™ and sealed with a coverslip.
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2.7.5  Luxol fast blue-Periodic acid-Schif stain
Te  samples  were  rehydrated  incompletely  (stop  afer  96 %  EtOH)  and
incubated  O/N  at  56 °  in  0.1 %  LFB  solution  (ABCR  GMBH  &  CO.  KG,
Karlsruhe, Germany, diluted with 96 % EtOH / 0.05 % acetic acid). Ten they
were washed in 96 % EtOH and incubated in 0.1 % lithium carbonate (Li2CO3)
for 30 sec. Te samples were washed very briefy in 70 % EtOH and distilled
water before incubation for 10 min in 0.8 % periodic acid (H5IO6) to wash of
excess  Li2CO3.  Afer  washing  with  distilled  water,  the  specimens  were
incubated in Schif reagent for 20 min. Excess reagent was washed of with
sulfte  washing solution (0.1 % of  concentrated (37 %)  HCl,  4 % potassium
metabisulfte (K2S2O5)  in H2O). Prior fnal dehydration and embedding, the
samples were washed extensively in non-distilled water for 10 min.
2.7.6 Bielschowsky’s silver stain for axons
Prior to further processing, samples were completely rehydrated. Next, the
samples  were  incubated  for  15 min  at  37 °  in  preheated  silver  nitrate
(AgNO3) and were washed aferward in distilled water. During this washing
step,  ammonia  (NH3)  is  given  to  the  previously  used  AgNO3 solution  to
prepare silver hydroxide (AgOH). Te specimens were then incubated in this
solution for 10 min at 37 ° in the dark. Aferward, samples were washed
twice in 0.1 % NH3.  To the used AgOH, 11–15 drops of developer solution
(5.4 ml  37 %  formaldehyde  in  114.6 ml  H2O +  1  drop  of  65 %  nitric  acid
(HNO3)  + 0.5 g citric acid) were added. In this solution, the samples were
incubated for 4–10 min under gentle shaking. Te specimens were washed
briefy  in  0.1 %  NH3 and  distilled  water  before  fnal  dehydration  and
embedding. Te slides were stored at 4 ° in the dark.
2.7.7 Antibody stains
Specimens were completely rehydrated as described before boiling in 0.1 M
citric acid (pH 6.0) for 20 min in a microwave oven at 600 W. Afer cooling
down  to  RT,  the  samples  were  washed  in  distilled  water  and  PBS
(2 min,4 changes  each)  followed  by  incubation  in  3 %  hydrogen  peroxide
(H2O2) in PBS for 10 min. Te binding sites were then blocked by incubation
in 10 % FCS / 0.02 % Triton X-100 in PBS for 10 min. Primary antibodies were
applied in blocking bufer O/N at 4 °. Afer washing with PBS, secondary,
biotinylated  antibodies  were  applied  at  RT  for  60 min.  Afer  additional
washing, a streptavidin-peroxidase complex (ExtrAvidin®-Peroxidase, SIGMA-
ALDRICH)  was  applied  to  the  specimens  (incubation  at  RT,  60 min).
Diaminobenzidine (DAB, 2g dissolved in 80 ml PBS) was used as a substrate
for oxidation which results in a dark-brown color (10 min incubation, RT).
By that,  the antibody labeled proteins could be visualized. Te specimens
were counterstained with Mayer's hemalum solution to visualize cell nuclei.
Aferward, the samples were dehydrated, embedded and stored at RT.
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Table 2.6 | Primary antibodies used in immunohistochemistry
Antigen Dilution Host Clonality Company
CD3 1:1000 Rat Polyclonal BD PHARMINGEN™
MAC3 1:1000 Rat Polyclonal BD PHARMINGEN™
Iba1 1:1000 Rabbit Polyclonal WAKO
Table 2.7 | Secondary antibodies used in immunohistochemistry
Antigen Dilution Host Clonality Company
Rat IgG 1:200 Rabbit Polyclonal VECTOR LABORATORIES
(Burlingame, California, USA)
Rabbit IgG 1:200 Rat Polyclonal VECTOR LABORATORIES
2.7.8 Image acquisition
Pictures were taken with an Olympus BX51 microscope equipped with an
UPlan FL N 10× or 20× lens and processed with analySISB imaging sofware
(each OLYMPUS, Shinjuku, Tokyo, Japan).
2.8 Imaging of Subcellular Calcium Signals
2.8.1 Preparation of cells for calcium signal measurements
Astrocytes were seeded on a chambered microscope slide (µ-Slide 8 Well,
IBIDI GMBH,  Planegg  /  Martinsried,  Germany)  in  a  concentration  of  5–
10 × 104 cells per well. Te cells were incubated with membrane permeable
AM esters of Ca2+ dyes Fluo-4 and Fura-2 (10 µM each) in 0.04 % Pluronic
F-127 (SIGMA-ALDRICH) for 30 min at 37 ° in the dark. Next, the cells were
washed once with Ca2+ bufer (140 mM NaCl, 5 mM KCl, 1 mM MgSO4, 1 mM
CaCl2, 20 mM HEPES, 1 mM NaH2PO4, 5 mM glucose, pH 7,4) before further
incubation in Ca2+ bufer for 20 min at RT in the dark for de-esterifcation.
All substances for stimulation were applied in Ca2+ bufer.
2.8.2 Image acquisition and processing
An  DM  IRBE  microscope  (LEICA MICROSYSTEMS, Wetzlar,  Germany)  with
100×  magnifcation  was  used  in  combination  with  a  DG-4  light  source
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(SUTTER INSTRUMENTS, Novato, California, USA). Images were acquired every
5 sec  over  a  total  time  of  20 min  using  an  EM-CCD  C9100  camera
(HAMAMATSU PHOTONICS,  Hamamatsu, Japan) with a resolution of 512×512
pixels (14-bit color depth; 2× binning) and a DualView module (PERKINELMER,
INC.). Te following flter set (AHF ANALYSENTECHNIK, Tübingen, Germany)
was  used  for  acquisition:  Exitation  λ=480/40 nm;  beamspliter  λ=495 nm;
emission1 λ=542/50 nm; emission2 λ=650/57 nm). Acquisition was performed
using the Volocity v6.6.2 sofware (PERKINELMER, INC.).
2.8.3 Data evaluation
Image processing using the Fiji v1.47 sofware (GPL v2) allowed spliting of
frames  acquired  with  the  DualView  module  into  the  two  wavelength
channels  for  post-measurements  and  calculation  of  the  Fura-2 / Fluo-4
emission  wavelength  ratio  (using  Openlab  sofware  v5.5.2,  PERKINELMER,
INC.)  as described (KUNERTH et  al.,  2003;  WOLF et  al.,  2015, manuscript in
revision).
2.9 Statistics
If not declared otherwise, data are always depicted as mean + standard error
of the mean (SEM). Methods for statistical evaluation were indicated in each
fgure and annotated with the following p-values: ns P ≥ 0.05, *P ≤ 0.05, **P ≤
0.01 and ***P ≤ 0.001.
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3.1 RyR1 and RyR3 in immune cells
Te elevation of intracellular free Ca2+  ([Ca2+]i) provides a major signal for
T cell activation upon antigen recognition. Within the cell, the endoplasmic
reticulum (ER)  is  the  main storage  compartment  for  free  calcium,  whose
release into the cytosol is mediated by two types of calcium channels—IP3
receptors  and  ryanodine  receptors  (RyRs)—upon  activation  by  second
messengers. It has been suggested recently that RyRs constitute a potential
target  for  the  second  messenger  NAADP in  Jurkat  and  Lewis  rat  T cells
(DAMMERMANN et  al.,  2009).  It  was  demonstrated  that  pharmacological
antagonism  of  NAADP  strongly  reduced  RyR  mediated  intracellular  Ca2+
signals in Jurkat T cells and rat TMBP  cells.  Furthermore, efector TMBP  cells
were more susceptible to NAADP antagonism than naïve or memory T cells,
and expression of  the RyR isoforms RyR1 and RyR3 was up-regulated in
efector  T cells.  Te impact  of  NAADP antagonism on Ca2+  signaling was
supported by the fnding that antagonizing NAADP during Lewis rat EAE
signifcantly  ameliorated  the  course  of  the  disease (DAMMERMANN et  al.,
2009).
For this study, Ryr knockout mice were used to investigate the role of RyRs
in the murine immune system and to evaluate the NAADP–RyR signaling
pathway as a potential target for treatment of autoimmune diseases of the
CNS. 
3.1.1 Ryr1 and RyR3 mRNA is expressed in efector T cells
Multiple  sclerosis  (MS)  and  its  animal  model  experimental  autoimmune
encephalomyelitis  (EAE)  are  described  as  T cell  mediated  infammatory
diseases (MILLER et al., 2007). As part of EAE pathology, T cells recruit other
leukocyte populations like B cells and macrophages into the CNS, thereby
sustaining the disease and damaging the CNS (PIERSON et al., 2013). In order
to investigate the function of RyRs in T cells and EAE, the expression of Ryr1
and  Ryr3 mRNA in immune cells of WT C57BL/6 mice was determined by
means of qRT-PCR. Terefore, naïve T cells (CD4+CD62LhighCD44low), efector
T cells (CD4+CD62LlowCD44high), naïve B cells (B220+CD19+), activated B cells,
and dendritic cells (DCs; CD11c+) were analyzed (Fig. 3.1). Consistent with
previous studies,  Ryr1 and  Ryr3 mRNA was not detectable in naïve T cells,
but present in efector T cells. No expression of Ryr1 and Ryr3 mRNA were
found either in naïve or activated B cells. In DCs, only minimal amounts of
Ryr1 and Ryr3 mRNA were detected (Fig. 3.1).
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Fig.  3.1 |  Ryr1 and  Ryr3 mRNA  expression  in  immune  cells.  Naïve  T cells
(CD4+CD62LhighCD44low) and MOG-specific B cells  (B220+CD19+)  were isolated from mixed
populations  of  lymph  node  cells  and  splenocytes.  Efector  T cells  were  enriched  from
draining lymph nodes of mice immunized against MOG35-55 peptide. B cells were activated
in vitro with 100 ng/ml LPS and 10 µg/ml MOG35-55. Dendritic cells (CD11c
+) were a kind gif
from my colleague Tanja Litke. Bars represent the mean (+SEM) from three independent
experiments normalized to the expression of beta-actin.
3.1.2 RyR1 and RyR3 are expressed in efector T cells in vitro
Having demonstrated that expression of Ryr1 and Ryr3 mRNA was found in
efector T cells, we analyzed the kinetic of RyR expression in T cells upon
unspecifc  stimulation  with  monoclonal  antibodies  or  antigen-specifc
(MOG35-55  peptide)  stimulation  in  vitro (Fig.  3.2).  We  cultured  total
splenocytes of C57Bl/6 WT and TCRMOG (2D2, MOG-specifc TCR transgenic)
mice in the presence of anti-CD3/anti-CD28 antibodies and MOG35-55 peptide,
respectively,  and  analyzed  CD4+ T cells  24 h,  48 h,  72 h,  and  96 h  afer
stimulation.  Ryr1 and Ryr3 mRNA expression was determined by qRT-PCR.
Increased levels of  Ryr1 mRNA were detected in T cells 48 h to 96 h afer
antibody stimulation, while Ryr3 mRNA was not detected. Afer stimulation
with MOG35-55 peptide, Ryr1 mRNA levels were increased in CD4
+ T cells 72 h
and 96 h afer stimulation, and low levels of Ryr3 mRNA were detected 96 h
afer stimulation.
Cells from the samples that were used for mRNA expression analysis were
also used for immunocytochemistry for RyR1 and RyR3 expression (Fig. 3.3).
According to the corresponding mRNA data, T cells expressed RyR1 72 h to
96 h afer anti-CD3/anti-CD28 antibody treatment and both RyR1 and RyR3
72 h  to  96 h  afer  stimulation  with  MOG35-55  peptide.  By  that,  we  could
confrm expression of RyR1 and RyR3 in activated T lymphocytes.
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Fig. 3.2 |  Ryr1 and Ryr3 mRNA expression in efector T cells.  Lef panel: Lymph node cells
and splenocyte cultures from WT C57Bl/6 mice were stimulated with 1 µg/ml anti-CD3 and
5 µg/ml anti-CD28 antibodies. Right panel: Lymph node cells and splenocyte cultures from
2D2 mice were stimulated with 10 µg/ml MOG35-55 peptide. At indicated time points, T cells
were  purified  via  negative  selection  and  used  for  mRNA  isolation  and  real-time  PCR
analysis  for  Ryr1 and  Ryr3.  Bars  represent  the  mean  (+SEM)  from  three  independent
experiments.
Fig. 3.3 | RyR1 and RyR3 protein expression in efector T cells. The expression of RyR1 and
RyR3  was  assessed  by  ICC  at  indicated  time  points.  (A), (B):  Lymph  node  cells  and
splenocyte cultures from WT mice were stimulated with 1 µg/ml anti-CD3 and 5 µg/ml anti-
CD28 antibodies.  (C) –  (F): Lymph node cells and splenocyte cultures from TCRMOG mice
were stimulated with 10 µg/ml MOG35-55 peptide. T cells were purified via negative selection
before fixation and antibody staining against RyR1 or RyR3. Nuclei were visualized with
DAPI. Scale bar represents 25 µm.
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3.2 Generation and analysis of  Ryr1-/-, Ryr3-/- and
Ryr double knockout fetal liver chimeras
Te  Ryr1  gene  knockout  results  in  early  postnatal  lethality  in  mice
(TAKESHIMA et al.,  1994).  Yet  to  investigate  the  efect  of  Ryr1  deletion  in
immune cells,  Ryr1-/-→WT fetal liver chimeras (FLCs) were generated (Fig.
3.4, A). For this purpose, hematopoietic progenitor cells derived from livers
of Ryr1-/- fetuses were isolated at 14.5 days post conception and injected into
lethally irradiated WT C57Bl/6 animals. Expression of the RFP reporter gene
thereby allowed further identifcation of the newly generated donor cells.
Blood analysis by FACS showed that reconstitution levels of hematopoietic
cells  was  about  75–80 %  for  T cells  (TCRβ+RFP+)  and  about  80–85 %  for
B cells (B220+RFP+) four weeks afer transfer (Fig. 3.4, B).
Fig. 3.4 |  Scheme for the generation of fetal liver chimeras. See text and methods chapter
2.4.2 for detailed description.
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Aferward,  the  mice  were  either  used  for  phenotyping  analyses  or  EAE
induction.  In parallel  to  generating  Ryr1-/-→WT FLCs,  Ryr3-/-→WT FLCs,
Ryr1 and  Ryr3  double  knockout  FLCs,  respective  heterozygous  controls
(Ctrl→WT; Ctrl) were generated and analyzed as well.
3.2.1 Te immune system of Ryr-KO FLCs does not difer from that
of control FLCs
Chimeric mice presented healthy and showed no obvious abnormalities. Te
status and composition of the immune system in chimeras was examined in
its naïve state. Tymi and spleens had normal appearance (not shown) and
were similar in weight and cellularity (Fig. 3.5).
Fig. 3.5 | Analysis of hematopoietic organs of fetal liver chimeric mice. In comparison with
control  mice,  thymus  and  spleen  of  Ryr3-/- mice  were  not  altered  in  weight  (A)  and
cellularity (B). Bars represent the mean (+SEM) from three independent experiments.
Lymphoid progenitors generated in the bone marrow home to the thymus
where  they  develop  into  mature  T cells.  During  this  process  several
checkpoints operate in a manner dependent on the TCR engagement and
Ca2+ signaling.  Tymocytes  diferentiate  from CD4-CD8- (double  negative)
cells into CD4+CD8+ (double positive) cells and further into mature CD4+  or
CD8+  single positive cells. Tese transition is severely disturbed when key
signaling molecules, such as Zap70, are deleted. Terefore, the frequency of
transgenic  RFP  CD4+  and  CD8+  thymocytes  in  Ryr knockout  FLCs  was
assessed by FACS staining (Fig. 3.6). Neither Ryr1 nor Ryr3 deletion changed




Fig. 3.6 | The frequency of CD4+ and CD8+ cells in the thymus of Ryr-KO FLCs is similar to
that of control FLCs. Single cell suspensions of thymocytes were stained and analyzed via
flow cytometry for the expression of surface markers CD4 and CD8. To exclude host cells we
gated on the  RFP+ population.  Depicted  are  representative  flow cytometry  data  (upper
panel) and the quantification from three individually performed experiments (lower panel;
bars represent mean+SEM).
Furthermore, the composition of the peripheral immune system of  Ryr-KO
FLCs  was  investigated  in  spleen,  lymph nodes  and  blood.  Cells  of  these
organs did not difer from each other in the ratio of expression of the surface
markers CD4 and CD8 (helper vs. cytotoxic T cells), TCR-β and B220 (T cells







Fig. 3.7 |  Ryr-KO FLCs are similar to control FLCs in the composition of the peripheral
immune system. Analyzed were (A) spleen, (B) lymph nodes and (C) blood for the ratio of
CD4+ to CD8+ cells, T to B cells  (TCR-β / B220) and the ratio of efector to naïve T cells
(CD44 / CD62L; only data for spleen). Single cell suspensions of the indicated organs were
prepared  if  necessary,  depleted  for  erythrocytes  and  stained  for  the  respective  surface
markers for analysis in flow cytometry. To analyze transgenic cells only, cells were gated on
the RFP+ population. Depicted are representative flow cytometry data (upper panels) and




3.2.2 Ryr1 defcient  T cells  show  diminished  TCR  dependent
intracellular Ca2+ response
T cells lacking Ryr1 were less responsive to NAADP stimulation, and showed
diminished  intracellular  Ca2+  signals  upon  stimulation  with  anti-CD3
antibody conjugated beads (WOLF et  al.,  2015, manuscript in revision, and
Fig. 3.8; Data kindly provided by Insa Wolf and Bjoern-Philip Diercks from
the lab of Dr. A. Guse, UKE, Hamburg).
Fig.  3.8  |  Ryr1 deficient  T cells  show diminished  intracellular  Ca2+  response  upon  TCR
stimulation. Ryr1-/- and control T cells were loaded with the membrane permeable Ca2+ dyes
Fluo-4  and Fura-2 as  described (chapter 2.8.1)  and stimulated with anti-CD3 antibody
conjugated beads.
3.2.3 Ryr1 defcient lymphocytes proliferate less in response to anti-
CD3 antibodies stimulation
Ca2+ signals are an essential mechanism for T cell activation and prompt the
proliferative T cell response. However, inhibition of Ca2+ signals, for example
with BZ194, a NAADP antagonist, results in diminished T cell activation and
proliferation (DAMMERMANN et al., 2009). We investigated if the proliferation
of  Ryr knockout  lymphocytes  in  response  to  anti-CD3  stimulation  was
reduced compared to heterozygous control  cells  (Fig.  3.9).  T lymphocytes
from  Ryr1-/-→WT FLCs proliferated in a dose-dependent  manner to  anti-
CD3 stimulation, but signifcantly less in comparison to  Ryr1+/-→WT FLC
control cells (Fig. 3.9, A). Te same was observed when cells were strongly
stimulated  with  anti-CD3/anti-CD28  antibodies.  In  Ryr-DKO→WT
lymphocytes, the proliferative response was similarly reduced, but not more
than in Ryr1 single KO cells. Obviously an additional knockout of Ryr3 had
no further efect on proliferation (Fig. 3.9, B). Tis became clearer when the
proliferation of lymphocytes from Ryr3-/-→WT FLCs was analyzed (Fig. 3.9,
C). Lymphocytes from  Ryr3-/-→WT FLCs proliferated in a dose dependent
manner to anti-CD3 antibody stimulation, but with no signifcant reduction
to the control group. Cells from either control or chimeric mice proliferated
substantially to stimulation with anti-CD3/anti-CD-28 antibodies and did not
proliferate when lef unstimulated.
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Fig. 3.9 |  The knockout of  Ryr1, but not of  Ryr3 atenuates the proliferative response of
T lymphocytes  derived  from  Ryr1-/-→WT  and  Ryr-DKO→WT  FLCs  in  comparison  to
control FLCs (Ryr1+/-Ryr3+/-→WT). Cells were isolated from the LNs of (A) Ryr1-/-→WT, (B)
Ryr-DKO→WT, and (C) Ryr3-/-→WT FLCs.  From single cell suspensions of LN cells, 3×105
cells  per  well  were  stimulated  for  48 h  with  anti-CD3  and/or  anti-CD28  antibodies  in
indicated  concentrations  before  chasing  with  3[H]thymidine  for  another  16 h  and
measurement of  3[H]thymidine incorporation. Medium (Med) served as negative control.
Each  condition  was  analyzed  in  triplicates.  Bars  represent  the  mean  (+SEM)  of  three
independent experiments. Statistical analysis was performed using a two-tailed Student’s t-
test (*P ≤ 0.05).
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3.2.4 EAE induction in Ryr1-/-→WT FLCs
To assess the role of RyR1 in EAE, Ryr1-/-→WT FLCs and respective control
FLCs were immunized against MOG35-55 peptide (Fig. 3.10).
Fig.  3.10 |  Ryr1-/-→WT FLCs  develop  atenuated  EAE.  Control  (n=20)  and  Ryr1-/-→WT
(n=20)  FLCs were immunized against MOG35-55 peptide.  (A)  EAE disease course and  (B)
weight change course of Ryr1-/-→WT FLCs (blue line) and control FLCs (Ryr1+/-Ryr3+/-→WT;
grey line). In (C) the day of disease onset and in (D) the percentage of disease free animals
are shown for each group. In all panels the mean (+SEM) of three independent experiments
is shown. Data were tested for statistical significance using the Mann–Whitney U test for
clinical courses (A, B; **P ≤ 0.01; *P ≤ 0.05) and a two-tailed Student’s t-test (C; ns P ≥ 0.05).
Ryr1-/-→WT FLCs developed frst clinical symptoms about one day later than
control animals (Fig. 3.10, A, C and D). Also, the progress of the disease
during  the  acute  phase  was  slightly  delayed  in  Ryr1-/-→WT  FLCs  and
resulted  in  a  milder  disease  at  the  peak  than  that  of  control  FLCs.  Te
chronic phase was characterized in both groups by persisting EAE symptoms
that were, however, signifcantly less pronounced in Ryr1-/-→WT FLCs (Fig.
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3.10, A). In concordance with the clinical scores, Ryr1-/-→WT mice lost less
weight during the course of EAE compared to control FLCs (Fig. 3.10, B).
Terefore ablation of Ryr1 in hematopoietic cells reduces the clinical severity
of EAE.
3.2.5 EAE induction in Ryr-DKO→WT FLCs
Ryr-DKO→WT FLCs developed a disease onset and an acute phase that was
similar  to  that  of  control  animals  (Fig.  3.11,  A,  C  and D).  Tis  was  in
contrast to the EAE observed in Ryr1-/-→WT FLCs. However, the peak and
the  EAE  progress  was  atenuated  in  Ryr-DKO→WT  FLCs.  Furthermore,
some of the mice partially recovered from EAE symptoms, which was not
observed in control animals or Ryr1-/-→WT FLCs. Likewise in EAE of Ryr1-/-
→WT FLCs,  Ryr-DKO→WT FLCs lost less weight than control FLCs (Fig.
3.11, B).
Fig. 3.11 | Ryr-DKO→WT FLCs develop atenuated EAE. Control (n=6) and Ryr-DKO→WT
(n=7)  FLCs  were  immunized against  MOG35-55 peptide.  (A)  EAE disease  course,  and  (B)
weight change course of  Ryr-DKO→WT FLCs (green line) and control FLCs (Ryr1+/-Ryr3+/-
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→WT; grey line). (C) Day of disease onset and (D) percentage of disease free animals for
each group.  In  all  panels  the  mean (+SEM) of  two independent  experiments  is  shown.
Statistics were carried out using the Mann–Whitney U test for clinical courses (A; *P ≤ 0.05)
and a two-tailed Student’s t-test (B, C; *P ≤ 0.05).
We concluded that mice developed an atenuated course of EAE as far as
Ryr1 was deleted in hematopoietic cells as a single knockout or as a double
KO in combination with Ryr3.
3.2.6 EAE induction in Ryr3-/-→WT FLCs
Our data on the expression of Ryr3 in T cells and proliferative response of
Ryr3 defcient  T cells  are  in  agreement  with  previously published results
(TAKESHIMA et al., 1996). Consistently,  Ryr3-/-→WT FLCs developed EAE on
about the same day afer immunization such as the control FLCs (Fig. 3.12,
A, C and D). Te onset and the acute phase of EAE proceeded similar in
Ryr3-/-→WT and control FLCs and EAE symptoms peaked about that same
day post  immunization.  In  contrast  to  the  amelioration  noticed  in  Ryr1-/-
→WT FLCs in the chronic phase, the disease progress was rather similar
between Ryr3-/-→WT FLCs and control FLCs. Even though EAE progressed
by tendency slightly milder in Ryr3-/-→WT FLCs, the diference did not reach
statistically signifcance levels, whereas weight loss of Ryr3-/-→WT FLCs was
signifcantly less severe compared to control mice (Fig. 3.12, B). However,
these results showed that deletion of  Ryr3 in hematopoietic cells had only
minor infuence on the clinical course of EAE.
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Fig.  3.12 |  Ryr3-/-→WT FLCs  do  not  develop EAE diferent  from that  of  control  FLCs.
Control (n=15) and Ryr3-/-→WT (n=18) FLCs were immunized against MOG35-55 peptide. (A)
EAE disease  course,  and (B)  weight  change course  of  Ryr3-/-→WT FLCs  (red  line)  and
control FLCs (Ryr1+/-Ryr3+/-→WT; grey line). In (C) the day of disease onset and (D) the
percentage of disease free animals are shown for each group. In all panels the mean (+SEM)
from three independent experiments is shown. Groups were statistically tested using the
Mann–Whitney U test for clinical courses (A, B; *P  ≤ 0.05, ns P  ≥ 0.05) and  a two-tailed
Student’s t-test (C; ns P ≥ 0.05).
3.2.7 Characterization of Ryr-KO T cells at the onset of EAE
In  order  to  further  investigate  the  impact  of Ryr deletion  on  EAE
pathogenesis, the status of infltrating T cells in the CNS was analyzed in
Ryr1-/-→WT FLCs,  Ryr-DKO→WT FLCs and control FLCs at d14 p. i. (Fig.
3.13).  To characterize  their  activation status,  T cells  were  stained  for  the
surface markers CD25 and CD69. It was found that T cells in the CNS from
Ryr1-/-→WT FLCs were less activated than those from control FLCs.
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Fig. 3.13 | Encephalitogenic T cells from Ryr1-/- and Ryr-DKO FLCs express lower amount of
the activation markers CD69 and CD25 and infiltrate less frequently into the CNS than
T cells  from  control  FLCs  (Ryr1+/-Ryr3+/-→WT).  Animals  were  sacrificed  on  d14  p. i.  to
recover T cells during the acute phase of EAE. Lymphocytes were isolated from the CNS
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using  Percoll  density  centrifugation.  Single  cell  suspensions  were  then stained for  flow
cytometry. To analyze only transgenic T cells, cells were gated on the CD4+RFP+ population.
Depicted are representative flow cytometry data (upper panels) and the quantification from
three  individually  performed  experiments  (lower  panel;  bars  represent  mean+SEM).
Statistical analysis was performed using a two-tailed Student’s t-test (*P ≤ 0.05, ns P ≥ 0.05).
3.3 Te function of RyR3 in the CNS during EAE
Te previous results indicated that a knockout of Ryr3 in hematopoietic cells
has no major efect on the clinical progression of EAE thus far as it was
observed  for  Ryr1-/-.  Accordingly,  the  T cell  function  was  not  severely
afected by Ryr3 deletion. However, in contrast to the rather low expression
levels in T cells, Ryr3 mRNA was found highly expressed in the brain and in
the spinal cord of WT C57Bl/6 mice (Fig. 3.14).
Fig. 3.14 | Ryr3 mRNA is highly expressed in the CNS. Homogenates from total brain (n=3)
and spinal cord (SC; n=3) were used for mRNA isolation and real-time PCR analysis.
3.3.1 EAE induction in WT→Ryr3-/- bone marrow chimeras
In order to further investigate the role of RyR3 in the CNS during EAE in
Ryr3-/- mice, bone marrow chimeras (BMCs) were generated by transferring
bone  marrow  cells  from  CD45.1  WT  mice  into  lethally  irradiated  Ryr3-/-
animals,  which  were  congenic  CD45.2.  CD45.1→Ryr3+/- BMCs  served  as
control animals. In contrast to Ryr3-/-→WT FLCs, these mice now exhibit the
knockout of  Ryr3 in the CNS (and other tissues), while hematopoietic cells
remain WT for RyR3. Afer successful reconstitution, EAE was induced by
immunization against MOG35-55  peptide (Fig. 3.15).  No obvious diferences
between CD45.1→Ryr3-/- and control animals were observed during the onset
and early clinical phase of EAE (Fig. 3.15 A, C and D). However 14–15 days
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afer  immunization  in  the  EAE  continued  to  progress  in  control
CD45.1→Ryr3+/- BMCs  but  not  in  Ryr3  KO  recipients.  (Fig.  3.15  A).  In
concordance with the clinical scores, CD45.1→Ryr3-/- BMCs lost less weight
during  the  course  of  EAE  compared  to  control  BMCs  (Fig.  3.15,  B).
Terefore,  defciency  of  RyR3  in  the  CNS—contrary  to  T cells  or  other
hematopoietic cells—was determining EAE severity. 
Fig.  3.15 |  Ryr3  deficiency  in  non-hematopoietic  cells  atenuates  EAE severity.  Control
(n=15) and WT→Ryr3-/- (n=15) BMCs were immunized against MOG35-55  peptide.  (A) EAE
disease course, and (B) weight change course of WT→Ryr3-/- BMCs (red line) and control
FLCs (grey line).  (C) Day of disease onset.  (D) Percentage of disease free animals. In all
panels the mean (+SEM) of three independent experiments is shown. Statistics were carried
out using the Mann–Whitney U test for clinical courses (A,  *P  ≤ 0.05) and a two-tailed
Student’s t-test (B, C; *P ≤ 0.05, ns P ≥ 0.05).
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3.3.2 Active EAE in Ryr3-/- mice
For the further experiments, mice with a germline knockout of  Ryr3 were
used.  In  contrast  to  Ryr1 knockout  animals,  mice  homozygous  for  Ryr3
deletion  were  healthy  and  fertile—though  hyperlocomotion  and  impaired
learning and memory were reported (TAKESHIMA et al.,  1996,  KOUZO et al.,
1999).  In  these  mice,  EAE  could  be  efectively  induced  by  immunization
against MOG35-55  peptide (Fig. 3.16). No diference in disease incidence was
found between control (Ryr3+/-) and Ryr3-/- mice (Fig. 3.16 A, C and D). Both
groups developed EAE at day 9-10 afer immunization and shared a similar
early clinical phase of EAE (Fig. 3.16 A and C). However, the peak of EAE
was reached 3-4 days earlier in  Ryr3-/- animals and presented signifcantly
lower clinical scores (Fig. 3.16 A). While control animals developed EAE as
expected (MENDEL et al., 1995), clinical symptoms of Ryr3-/- mice signifcantly
improved during the chronic phase of EAE. 
Fig. 3.16 | Ryr3-/- mice develop atenuated EAE. Control (n=20) and Ryr3-/- mice (n=20) were
immunized against MOG35-55 peptide. (A) EAE disease course, and (B) weight change course
of Ryr3-/- (red line) and control mice (grey line).  (C) Day of EAE onset.  (D) Percentage of
disease free animals. In all panels the mean (+SEM) of three independent experiments is
shown. Statistics were carried out using the Mann–Whitney U test for clinical courses (A,
B; **P ≤ 0.01; *P ≤ 0.05) and a two-tailed Student’s t-test (C; ns P ≥ 0.05).
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3.3.3 Histology of Ryr3-/- EAE animals
Demyelination  and  axonal  degeneration in  the  spinal  cord  are  the  main
histopathological  features  of  EAE  that  result  from  infltration  of
encephalitogenic T cells and recruited macrophages. In order to characterize
the pathology of EAE in  Ryr3-/- mice, animals were analyzed at day 17 post
immunization,  when  mice  of  the  control  group  were  at  the  peak  of  the
disease. Fixed spinal cord tissue was used for preparation of parafn sections
and  further  analyzed  by  IHC  for  the  frequency  of  infltrating  T cells,
macrophages and activated microglia.
To determine the quantity of infltrating T cells, tissue sections were stained
for CD3+  T cells (Fig. 3.17, A). It was found that the number of T cells in
spinal cord sections of  Ryr3-/- mice was signifcantly reduced compared to
controls. A highly signifcant reduction in cell  infltrates was found when
spinal  cord  sections  were  stained  for  the  number  of  recruited  MAC3+
macrophages (Fig. 3.17, B). 
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Fig. 3.17 |  Less immune cells infiltrate the spinal cords of Ryr3-/- mice at the peak of EAE.
Control (n=4) and  Ryr3-/-  (n=4) mice were immunized against MOG35-55. Spinal cords were
isolated at the peak of EAE (d17 p. i.)  and used for parafin sections. Antibody stainings
were performed for (A) CD3 (T cells) and (B) MAC3 (macrophages) and counterstained with
Mayer's hemalum solution to visualize cell nuclei. For the statistical analysis, at least five
sections from the cervical, thoraic and lumbar segment were investigated for each spinal
cord.  Bars  represent  mean  (+SEM).  Data  were  statistically  tested  using  a  two-tailed
Student’s t-test (**P ≤ 0.01, *P ≤ 0.05). Representative images are shown from animals with a
clinical score of 6.0 (control) and 3.5 (Ryr3-/-).
Microglia  are  CNS  resident  immune  cells  of  hematopoietic  origin  that
permanently  scan  tissue  for  damage  or  infections.  During  infammation
microglia cells accumulate at the pathological site and can act as antigen-
presenting  cells  for  T helper  cells.  As  they  are  potent  producers  of  pro-
infammatory cytokines, they highly contribute to neuroinfammation. Upon
activation, microglia change their morphology from a ramifed to a roundish
shape  and  strongly  up-regulate  Iba1  expression,  Signifcantly  less  Iba1+
microglia/activated  macrophages  were  counted  in  spinal  cord  sections  of
Ryr3-/-  mice  compared  to  controls  (Fig.  3.18).  It  was  also  observed  that
microglia were distributed more even in spinal cords from  Ryr3-/-  mice but
accumulated dense at infammatory sites in control animals.
Fig. 3.18 | Less microglia co-localize at inflammatory sites in spinal cords of Ryr3-/- mice at
the peak of EAE. Control (n=4) and  Ryr3-/-  (n=4) mice were immunized against MOG35-55.
Spinal cords were isolated at the peak of EAE (d17 p. i.)  and used for parafin sections.
Antibody  stainings  were  performed  for  microglia  marker  Iba1  and  counterstained  with
Mayer's hemalum solution to visualize cell nuclei. For the statistical analysis, at least five
sections from the cervical, thoraic and lumbar segment were investigated for each spinal
cord.  Bars  represent  mean  (+SEM).  Data  were  statistically  tested  using  a  two-tailed
Student’s t-test (**P ≤ 0.01). Representative images are shown from animals with a clinical
score of 6.0 (control) and 3.5 (Ryr3-/-).
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Autoimmune infammation of the CNS results in demyelination and axonal
degradation. Te extent of demyelination was assessed at the peak of EAE by
Luxol fast blue-Periodic acid-Schif stain (LFB-PAS; Fig. 3.19, A), while axon
degradation was investigated by means of Bielschowsky’s silver stain (BSS)
in  the  chronic  phase  of  EAE,  30 days  afer  immunization  (Fig.  3.19,  B).
Spinal  cord  sections  of  Ryr3-/- mice  showed  a  signifcant  reduction  in
demyelination and axonal pathology.
Fig. 3.19 |  Demyelination and axonal loss are significantly reduced in Ryr3-/-  mice. Control
(n=4) and  Ryr3-/-  (n=4) mice were immunized against MOG35-55 peptide.  (A) Spinal cords
were isolated at the peak of EAE (d17 p. i.) and used for parafin sections. To evaluate the
amount of demyelination, slides were stained with LFB solution to detect myelin, combined
with a PAS reaction to visualize exposed glycoproteins in the demyelinated regions. The
percentage of demyelination was calculated for the area of the white mater.  (B) Spinal
cords  were  isolated  at  d30  p. i.  for  detection  of  axonal  degradation  by  means  of
Bielschowsky’s silver stain that gives nerve fibers a dark color. The percentage of axonal loss
was calculated for the area of the white mater. For the statistical analysis, at least five
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sections from the cervical, thoracic and lumbar segment were investigated for each spinal
cord.  Bars  represent  mean  (+SEM).  Data  were  statistically  tested  using  a  two-tailed
Student’s t-test (**P ≤ 0.01, *P ≤ 0.05). Representative images are shown from animals with a
clinical score of 6.0 (control) and 3.5 (Ryr3-/-) in (A), and a clinical score of 5.0 (control) and
3.0 (Ryr3-/-) in (B). 
3.3.4 Spontaneous EAE in Ryr3-/-×2D2×IgHMOG mice
Induction of  EAE is generally performed by active immunization of  mice
against myelin antigens, e. g. MOG35-55  applied in strong immune adjuvants,
or by the injection of pre-activated myelin specifc T lymphocytes. Yet, it has
been reported that mice that were generated by crossing MOG-specifc T cell
receptor transgenic 2D2 (TCRMOG) mice with IgHMOG mice (harbouring MOG-
specifc  B cells)  develop  EAE  spontaneously  (BETELLI et  al.,  2006,
KRISHNAMOORTHY 2006). To investigate how deletion of  Ryr3 infuences the
course  of  spontaneous  EAE (spEAE),  Ryr3-/-×2D2  mice  were  crossed  with
IgHMOG  mice  and  followed  several  months  for  the  occurrence  of  EAE
symptoms  (Fig.  3.20).  As  in  the  previous  experiments,  Ryr3+/-  litermates
served as control animals.
Ryr3-/- developed spEAE about 80 days afer birth, whereas control animals
developed frst  clinical  symptoms already with an average age of  48 days
(Fig. 3.20, B). From the group of Ryr3-/- animals 40 % developed no disease at
all, while only 20 % of control animals remained without clinical symptoms
at  the end of  the observation period (Fig. 3.20, C).  Compared to control
animals,  Ryr3-/- mice  developed less  severe  EAE symptoms (Fig.  3.20,  A).
Similar  to  the  EAE  induced  by  active  immunization,  Ryr3-/- and  control
animals showed an identical clinical course of EAE during disease onset, but
difered at the peak and in the chronic phase of the disease. While control
animals developed disease with full paralysis of the hind limbs, gang ataxia
was the most severe symptom in Ryr3 defcient animals.
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Fig. 3.20 | Spontaneous EAE in  Ryr3 deficient mice. Control (n=5) and  Ryr3-/- mice (n=5)
were monitored daily for the (spontaneous) development of EAE symptoms. (A) EAE disease
course of Ryr3-/-×2D2×IgHMOG (red line) and control mice (grey line). (B) Day of onset of each
group.  (C)  Percentage of  disease  free  animals.  In  all  panels  the  mean (+SEM) of  three
independent experiments is shown. Statistics were carried out using the Mann–Whitney U
test for clinical courses (A, *P ≤ 0.05) and a two-tailed Student’s t-test (B; *P ≤ 0.05).
3.3.4.1 Histology of Ryr3-/-×2D2×IgHMOG EAE animals
Spinal cord sections of  Ryr3-/-×2D2×IgHMOG EAE mice were prepared at the
end  of  the  observation  period  (Fig.  3.21).  No  remaining  immune  cell
infltrates—either  positive  for  CD3  or  MAC3—were  found  in  spinal  cord,
neither in control nor in Ryr3-/- mice at this time point of EAE (not shown).
Yet, demyelination was signifcantly reduced in  Ryr3-/- mice, as well as the
intensity of axonal degradation.
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Fig. 3.21 |  Demyelination and axonal loss are reduced in Ryr3-/-×2D2×IgHMOG mice. Spinal
cords (n=4 for each group) were isolated at the end of the observation period (d30 afer
spEAE onset) and used for parafin sections. (A) shows the evaluation of demyelination.
Samples  were  stained  with  luxol  fast  blue  solution  to  detect  myelin,  combined  with  a
periodic acid-Schif reaction to visualize exposed glycoproteins in the deymelinated regions.
The percentage of demyelination was calculated for the area of the white mater. (B) shows
the  evaluation  of  axonal  degradation  by  means  of  Bielschowsky’s  silver  stain.  The
percentage of axonal loss was calculated for the area of the white mater. For the statistical
analysis,  at  least  five  sections  from  the  cervical,  thoraic  and  lumbar  segment  were
investigated  for  each  spinal  cord.  Bars  represent  mean  (+SEM).  Data  were  statistically
tested using a two-tailed Student’s t-test (*P ≤ 0.05). Representative images are shown from
animals with a clinical score of 6.0 (control) and 3.0 (Ryr3-/-).
3.3.5 Analysis of the immune system of Ryr3-/- mice
Te ablation of Ryr3 had benefcial efects on the progression of EAE, either
induced  by  active  immunization  or  under  spontaneous  conditions.  In
addition, the data from bone marrow and fetal liver chimeras strongly argue
that this extenuation was likely mediated by the deletion of RyR3 in cells of
the CNS rather than loss of RyR3 in hematopoietic cells. However, chimeric
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mice  never  display  a  complete  reconstitution  of  hematopoietic  cells.
Terefore, we analyzed the immune system of Ryr3 defcient mice in order to
reveal or exclude the role of Ryr3 expression in immune cells in described
results of EAE experiments.
First of all, thymus and spleen from Ryr3-/-  mice were indistinguishable from
those of heterozygous control litermates by visual inspection and did not
difer in organ weight or cellularity (Fig. 3.22). 
Fig.  3.22 |  Analysis  of hematopoietic organs of  Ryr3-/- mice. In comparison with control
mice,  thymus  and  spleen  of  Ryr3-/- mice  were  not  altered  in  size  (A),  weight  (B) and
cellularity (C). Bars represent the mean (+SEM) from three independent experiments.
Secondly, it was investigated if defciency of  Ryr3 had an impact on T cell
development in the thymus. Terefore,  thymocytes from  Ryr3-/- mice were
stained for CD4 and CD8 surface markers (Fig. 3.23). Ablation of  Ryr3 had
no obvious efect on the frequency of CD4+ or CD8+ single positive, as well as
double positive (CD4+CD8+) or double negative (CD4-CD8-) thymocytes.
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Fig. 3.23 | The frequency of CD4+ and CD8+ cells in the thymus of Ryr3-/- mice is similar to
that of controls. Single cell suspensions of thymocytes were stained and analyzed via flow
cytometry for the expression of surface markers CD4 and CD8. Depicted are representative
flow cytometry data (upper panel) and the quantification from three individually performed
experiments (lower panel; bars represent mean+SEM).
Furthermore,  the  composition  of  the  peripheral  immune  system  was
investigated in spleens and lymph nodes of  Ryr3-/- mice.  Te organs were
analyzed for the frequency of CD4+ and CD8+ T cells, naïve and efector CD4
T cells,  the  ratio  between  T  and  B cells  and  expression  of  the  surface
activation markers CD25 and CD69 (Fig. 3.24 and 3.25). Te status of the
immune  system  in  lymph nodes  was  similar  in  Ryr3-/- and  control  mice.
However, in Ryr3-/- mice there was a shif in the ratio of CD4+  to CD8+  cells
towards the cytotoxic T cell population. Tis was also observed in the spleen,
where this shif was even more pronounced. Apart from this, the immune
system of Ryr3-/- was virtually indistinguishable from that of controls.
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Fig. 3.24 | The composition of the immune system in LNs of Ryr3-/- mice is similar to that of
control mice. Single cell suspensions of lymph nodes from  Ryr3-/- mice were stained and
analyzed via flow cytometry for expression of surface markers CD4 and CD8, CD62L and
CD44, TCR-β and B220, CD25 and CD69. Depicted are representative flow cytometry data
(upper panel) and the quantification from three individually performed experiments (lower
panel; bars represent mean+SEM).
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Fig. 3.25 | The composition of the immune system in spleens of Ryr3-/- mice is similar to that
of control mice. Single cell  suspensions of spleens from  Ryr3-/- mice were depleted from
erythrocytes and stained and analyzed via flow cytometry for expression of surface markers
CD4  and  CD8,  CD62L  and  CD44,  CD25  and  CD69.  Depicted  are  representative  flow
cytometry  data (upper  panel)  and the quantification  from three  individually  performed
experiments (lower panel;  bars represent mean+SEM).  Statistical analysis was performed
using a two-tailed Student’s t-test (*P ≤ 0.05).
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3.3.5.1 Proliferation of Ryr3-/- lymphocytes
Ryr3-/- lymphocytes were tested for their proliferation abilities in response to
stimulation  with  anti-CD3  antibodies  or  MOG35-55  peptide  (on  the  2D2
transgenic  background),  respectively  (Fig.  3.26).  Lymph  node  cells
proliferated in a dose dependent manner to 48 h stimulation with anti-CD3
antibodies.  However,  no  diferences  were  observed  between  Ryr3-/- and
control  cells  (Fig.  3.26,  A).  Litle,  but  yet  signifcant  reduction  in
proliferation was observed when lymphocytes were strongly stimulated for
48 h with anti-CD3/anti-CD28 antibodies. Lymphocytes from mice with 2D2
(TCRMOG)  background proliferated  signifcantly  less  when stimulated  with
1.0 µg/ml  MOG35-55  peptide,  but  not  with  10 µg/ml,  where  only  tendency
levels in the reduction of proliferation were observed (Fig. 3.26, B). 
Fig.  3.26 |  The  knockout  of  Ryr3 does  not  severely  alter  the  proliferative  response  of
lymphocytes or splenocytes. Cells were isolated from LNs of Ryr3-/- mice (A), and spleen of
2D2-Ryr3-/- mice (B).  From single cell suspensions, 3×105 cells per well were stimulated for
48 h with anti-CD3 and/or  anti-CD28 antibodies  (A),  or  MOG35-55 peptide  or  ovalbumin
(OVA) (B) in indicated concentrations before chasing with 3[H]thymidine for another 16 h
and  measurement  of  3[H]thymidine  incorporation.  Medium  (Med)  served  as  negative
control. Each condition was analyzed in triplicates. Bars represent the mean  (+SEM) of three
independent experiments and were compared using a two-tailed Student’s t-test (*P ≤ 0.05).
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3.3.5.2 In vivo proliferation of Ryr3-/- T cells
As  a  consequence  of  immunization,  naïve  T cells  become  activated  by
dendritic cells through TCR stimulation. Tis stimulus results in rapid T cell
proliferation in the draining lymph nodes (JENKINS et al., 2001).
To  test  how T cells  from  Ryr3-/- mice  would  proliferate  in  the  secondary
lymphoid organs in vivo, CFSE-labeled, RFP+ CD4+ T cells from either Ryr3-/-
or control mice were transferred into C57BL/6 recipient mice.  Analysis of
T cell proliferation (CFSE dilution) was performed 48 h, 60 h, 72 h and 96 h
afer immunization against MOG35-55 peptide for the draining (inguinal and
popliteal LNs) and for the non-draining lymph nodes (cervical and axial LNs;
Fig. 3.27).  Even though  Ryr3 defcient T cells proliferated less in draining
lymph  nodes  than  control  T cells  at  every  investigated  time  point,
atenuation was only signifcant 96 h afer immunization. No diference in
proliferation  between  Ryr3-/- and  control  cells  was  observed  in  the  non-
draining lymph nodes.
Fig. 3.27 | Proliferation of MOG-specific T cells upon immunization is not afected by Ryr3
deficiency. An equal amount of isolated CD4+ MOG peptide-specific T cells was labeled with
CFSE and injected i.v. into C57Bl/6 host animals. Afer 48 h, mice were immunized against
MOG35-55 peptide (200 ng PTX d0 and d2 p. i.). Single cell suspensions from the draining and
non-draining lymph nodes were prepared 48 h, 60 h, 72 h and 96 h afer immunization. The
dilution of CFSE was analyzed by flow cytometry for the CD4+RFP+ cell population.  Bars
represent the mean (+SEM) of two independent experiments with two mice per time point




3.3.5.3 Encephalitogenic potential of Ryr3 defcient T cells
In  order  to  investigate  the  encephalitogenic  potential  of  Ryr3 defciant
T cells, we transfered MOG-specifc  Ryr3-/- cells (Ryr3-/-×2D2) in OT II mice,
followed by immunization against MOG35-55  peptide. T cells from OT II mice
are reactive against ovalbumin. Tis allowed the investigation how MOG-
specifc Ryr3-/- T cells contribute to EAE in an otherwise EAE resistant host.
We observed that EAE in mice that received  Ryr3-/-×2D2 T cells developed
not  diferently  from controls  (Fig.  3.28),  supporting  our  previous  results
indicating that Ryr3 deletion does not impair T cell function or the ability of
T cells to become encephalitogenic.
Fig. 3.28 | The  encephalitogenic potential of MOG-specific T cells is not afected by  Ryr3
deficiency. An equal amount of  Ryr3-/-×2D2 T cells and respective controls was transferred
into OT II mice 48 h prior immunization against MOG35-55 peptide. (A) EAE disease course of
OT II mice that received Ryr3-/-×2D2 cells (red line) and control cells (grey line). (B) shows
the percentage of survival of the animals. (C) Day of onset of each group. (D) Percentage of
disease free animals. In all panels the mean (+SEM) of three independent experiments is
shown. Statistics were carried out using the Mann–Whitney U test for clinical courses (A,
*P ≤ 0.05) and a two-tailed Student’s t-test (B; *P ≤ 0.05).
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3.3.5.4 Antigen recall assay
Afer priming in the secondary lymphoid organs, T cells start to proliferate
and gain  their  migratory phenotype that  allows them to enter  the  blood
circulation. In case of MOG35-55  peptide-induced EAE, T cells cross the BBB
and infltrate into the CNS, where they re-encounter their specifc antigen
and become reactivated and promote infammation.
Lymphocytes from draining lymph nodes and splenocytes were tested for
their  antigen  recall  response  at  day 8  post  immunization.  Te cells  were
isolated and restimulated with MOG35-55  peptide and assayed 48 h later (Fig.
3.29). As observed before lymphocytes and splenocytes proliferated in a dose
dependent manner to MOG35-55  peptide stimulation, but with no signifcant
diference between Ryr3-/- and control cells.
Fig. 3.29 |  Ryr3-/- lymphocytes from the periphery are not impaired to antigen recall afer
immunization.  MOG  peptide-specific  Ryr3-/- and  control  mice  were  immunized  against
MOG35-55 peptide. At d8 p. i., 3×10
5 cells per well from single cell suspensions of (A) LNs and
(B)  spleen  were  stimulated  for  48 h  with  MOG35-55 peptide  in  indicated  concentrations
before chasing with  3[H]thymidine for another 16 h and measurement of  3[H]thymidine
incorporation. Medium (Med) served as negative control. Each condition was analyzed in
triplicates. Bars represent the mean (+SEM) of three independent experiments.
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3.4 Te function of RyR3 in astrocytes during the
course of EAE
3.4.1 Expression of RyR3 in primary murine astrocytes
Astrocytes and microglia play active and crucial roles during EAE in several
ways, such as antigen presentation, chemokine and cytokine production, and
the provision of a suitable environment for T cell atraction and activation
(RAIVICH,  2005,  NAIR et  al.,  2008).  Primary  cultures  of  astrocytes  and
microglia were analyzed for expression of  Ryr3 mRNA. In contrast to the
steady state (Fig. 3.30, A), highly elevated levels of Ryr3 mRNA were found
in activated astrocytes, whereas activation of microglia resulted only in a
minor increase in  Ryr3 mRNA expression (Fig. 3.30, B). RyR3 protein was
detectable in astrocytic cultures by immunostaining presumably in the ER
compartment (Fig. 3.30, C).
Fig.  3.30 |  Ryr3 mRNA  is  highly  expressed  in  activated  astrocytes.  Cultures  of  (A)
unstimulated and (B) LPS stimulated (100 ng/ml) astrocytes (ACs) and microglia (MG) were
analyzed for Ryr3 mRNA expression. Expression of Ryr3 mRNA in midbrain neurons (Neu)
served as a reference. Bars represent the mean (+SEM) from three independent experiments.
RNA  lysates  from midbrain  neurons  were  a  kind  gif  from  Anna-Elisa  Roser,  Dept.  of
Neurology, University Medicine Götingen. (C) Functional RyR3 is expressed in astrocytes.
Primary cultures  of  astrocytes  (RFP) were stimulated with LPS (100 ng/ml)  and stained
against RyR3 (green). Nuclei were visualized with DAPI (blue). Scale bar represents 50 µm.
64
Results
3.4.2 Ryr3-/- astrocytes show laltered Ca2+ signaling responses
Astrocytes are linked in a network via intercellular channels also known as
gap junctions,  which  allow the  fast  passage  of  ions  and small  molecules
between cells. Stimulation of astrocytes evokes an increase of intracellular
Ca2+  that propagates to neighboring cells via the gap junctions, resulting in
progressive Ca2+  waves that spread throughout the astrocytic network. ATP
is a potent stimulator of intracellular Ca2+ signals in astrocytes (JEREMIC et al.,
2001) therefore we used this naturally occurring compound to investigate
Ca2+  signals  in  Ryr3-/-,  and  heterozygous  control  astrocytes.  Primary
astrocytes from neonatal mice were loaded with the membrane permeable
Ca2+ dyes Fluo-4 and Fura-2 as described (chapter 2.8.1) and stimulated with
30 µM ATP. Te resulting Ca2+  response was imaged for additional 20 min
(Fig. 3.31).
Neither control nor  Ryr3-/- astrocytes showed spontaneous Ca2+  fuxes when
imaged afer treatment with calcium bufer as vehicle control.  Substantial
Ca2+  signaling was detected when control cells were stimulated with 30 µM
or 50 µM ATP. A strong peak was observed 5–10 sec afer ATP application
and oscillating paterns in Ca2+ signaling were detected in some cells starting
afer  about  5 min  and  continued  until  the  end  of  the  measuring.  An
atenuated form of  this initial  peak and fewer oscillations—or oscillations
with lower amplitudes—were observed in  Ryr3-/- astrocytes. No initial spark
was  observed  when astrocytes,  either  controls  or  Ryr3-/-,  were  stimulated
with 12.5 µM ATP. However, some control cells began to oscillate afer about
10–12 min, which was not observed in Ryr3-/- cells.
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Fig.  3.31 |  Ryr3-/- astrocytes  show altered  Ca2+ signals  in  response  to  ATP stimulation.
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Astrocytes were loaded with the Ca2+ dyes Fluo-4 and Fura-2. The Fura-2 ratio (340/380 nm)
was imaged over total 20 min. Afer 1 min, the cells were stimulated with ATP. Calcium
bufer served as vehicle control. Depicted are the means of acquired Ca2+ signals of all cells
within the measuring field.
3.4.3 Ryr3-/- astrocytes secrete less glutamate upon stimulation
Glutamate is  an excitatory transmiter  which is  released by astrocytes  to
modulate the functions of nearby neurons (MALARKEY AND PARPURA,  2008)
and can be mediated by Ca2+ dependent exocytosis (PARPURA et  al.,  1994).
HUA et al. reported in 2004 that the Ca2+ that was necessary for the glutamate
release came mainly from internal stores and that an activation of IP3Rs and
RyRs was required. Primary astrocytes from Ryr3-/- mice were stimulated and
analyzed for their release of glutamate (Fig. 3.32).
Fig.  3.32 |  Glutamate  release  is  reduced  in  Ryr3-/- astrocytes.  Primary  astrocytes  were
stimulated  with  indicated  concentrations  of  IFN-γ/TNF-α or  30 µM ATP for  1 h  or  lef
untreated (medium control; Med). Levels of glutamate in the medium of astrocytes were
determined  by  colorimetric  quantification.  Bars  represent  the  mean  (+SEM)  of  three
independent experiments. Statistical analysis was performed using a two-tailed Student’s t-
test (*P ≤ 0.05, ns P ≥ 0.05).
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3.4.4 Ryr3-/- primary  astrocytes  produce  lower  amounts  of  CCL2,
CCL5, CXCL10 and TNF-α in vitro
In  general,  astrocytes  support  neuronal  transmission,  maintain  neuronal
integrity and control homeostasis of the BBB. In case of neuroinfammation
they  can  exert  both  neuroprotective  or  neurotoxic  functions  by  the
production of chemokines and cytokines (LIEBERMAN et al., 1989, CHOI et al.,
2014). LPS are large bacteria derived endotoxins that cause strong immune
responses and are known to induce chemokine and cytokine production in
astrocytes (LIEBERMAN et al., 1989). To investigate whether  Ryr3-/- astrocytes
responded  diferently  from  control  astrocytes  to  strong  stimuli,  LPS  was
applied to primary cultures of cortical astrocytes and RNA was isolated afer
4 h and 24 h of stimulation to analyze the expression of Ccl2, Ccl5, Cxcl10 and
Tnfa mRNA (Fig. 3.33). First of all  it  was observed that both control and
Ryr3-/- astrocytes did respond to LPS, either applied for 4 h or 24 h. However,
there was a substantial reduction in  Ccl2,  Ccl5 and  Tnfa mRNA expression
afer 4 h in  Ryr3-/- astrocytes, while no signifcant diference was found for
the  expression  of  Cxcl10 mRNA.  Te  same  tendency  was  observed  in
astrocytes that were stimulated with LPS for 24 h. Only background levels of




Fig. 3.33 | Chemokine and cytokine mRNA expression  in response to LPS stimulation is
reduced in Ryr3-/- astrocytes. Primary astrocytes were stimulated with 100 ng/ml LPS for 4 h
or 24 h or lef untreated (medium control; Med). Ryr3 mRNA levels were determined by real-
time PCR analysis.  Bars  represent the  mean (+SEM) of  three independent  experiments.
Statistical analysis was performed using a two-tailed Student’s t-test (**P ≤ 0.01, *P ≤ 0.05).
During EAE, IFN-γ and TNF-α were secreted by infltrating encephalitogenic
T1 cells in order to promote macrophage recruitment, and higher levels of
these cytokines were found in the CSF of MS patients (KROENKE et al., 2008).
Tus it was investigated how astrocytes would respond to these stimuli (Fig.
3.34). In addition, the cells were treated with ATP, which induced powerful
Ca2+ signals,  and glutamate,  a transmiter that was secreted by astrocytes
themselves upon stimulation as described (Fig. 3.31 and Fig. 3.32).
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Fig. 3.34 | Chemokine and cytokine mRNA expression is reduced in Ryr3-/- astrocytes afer
stimulation  with  IFN-γ/TNF-α.  Primary  astrocytes  were  stimulated  with  100 ng/ml
IFN-γ/TNF-α, 100 µM glutamate (Glu), 30 µM ATP or lef untreated (medium control; Med)
for 1 h.  Ryr3 mRNA levels were determined by real-time PCR analysis. Bars represent the
mean (+SEM) of three independent experiments. Statistical analysis was performed using a
two-tailed Student’s t-test (***P ≤ 0.001, **P ≤ 0.01, ns P ≥ 0.05).
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3.4.5 Astrocytes isolated from spinal cords of  Ryr3-/- mice produce
lower amounts of CCL2, CCL5 and CXCL10 at the onset of EAE
During the onset of EAE, chemokines regulate the migration of immune cells
towards sites of infammation and contribute to leukocyte infltration into
the CNS parenchyma (KUNKEL AND BUTCHER, 2002). Astrocytes have proven
to be a potent producer of chemokines in the context of neuroinfammation,
and particular in EAE (ENG et al., 1996). Since it was observed in vitro that
Ryr3-/- astrocytes were less responsive to stimuli and produced lower amounts
of  chemokines  and  cytokines,  Ryr3-/- astrocytes  of  EAE  mice  were
investigated ex vivo  at the onset of EAE. Spinal cords of EAE animals were
isolated and split longitudinally. One half of the spinal cord tissue was used
to isolate astrocytes via MACS purifcation, while the other half was used to
purify T cells  via negative selection. From both populations the RNA was
extracted and analyzed by qPCR. Astrocytes were analyzed for Ccl2, Ccl5 and
Cxcl10 mRNA expression (Fig.  3.35,  A)  and  T cells  for  the  expression of
chemokine receptor Cxcr3,  Cxcr4,  Ccr5,  Ccr6 and Ccr7 mRNA (Fig. 3.35, B).
Animals from both control and Ryr3-/- had a clinical score of 1.0 at the time
point  of  tissue  collection  (d11  p.  i.).  Tere,  astrocytes  from  Ryr3-/- mice
expressed  signifcantly  less  Ccl2,  Ccl5 and  Cxcl10 mRNA  compared  to
controls (Fig. 3.35, A). Additionally, T cells were investigated for expression
of  chemokine receptor  mRNA.  While  no signifcant  diferences  in mRNA
expression  levels  were  found  between  Ryr3-/-  and  control  cells,  levels  of
Cxcr3, Ccr6 and  Ccr7 mRNA were by tendency lower in  Ryr3-/- T cells.  In
neurodegenerative disorders, astrocytes are also known to express adhesion
molecules,  thus  facilitating  leukocyte  entry  into  the  CNS.  Among  these
molecules,  ICAM-1 and VCAM-1 were expressed by astrocytes  (DIETRICH,
2002, GIMENEZ et al., 2004), but expression levels were similar between Ryr3-/-
and control astrocytes at the onset of EAE (Fig. 3.35, C). 
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Fig. 3.35 | Chemokine and cytokine mRNA expression is reduced in Ryr3-/- astrocytes during
EAE,  while  there  were  no  changes  in  chemokine  receptor  mRNA  expression  in
encephalitogenic  T cells  of  the  same  animal. Ryr3-/- and  control  mice  were  immunized
against MOG35-55 peptide. Spinal cords were isolated from perfused animals at d11 p. i., and
astrocytes and T cells were either isolated by MACS or purified by gradient centrifugation
and  negative  selection.  Lysates  from  isolated  astrocytes  were  used  for  real-time  PCR
analysis for expression of Ccl2,  Ccl5 and Cxcl10 mRNA (A), while T cells were analyzed for
Cxcr3, Cxcr4, Ccr5, Ccr6 and Ccr7 mRNA expression (B). Bars represent the mean (+SEM) of
three  independent  experiments.  Statistical  analysis  was  performed  using  a  two-tailed
Student’s t-test (**P ≤ 0.01, *P ≤ 0.05, ns P ≥ 0.05).
3.4.6 Activation status and quantity of infltrating Ryr3-/- T cells
At the peak (d17 p. i.) of the EAE, fewer T cells and macrophages were found
in  spinal  cords  of  Ryr3-/- mice  (Fig.  3.17).  It  was  also  found  that  Ryr3-/-
astrocytes produced less chemokines at the onset of EAE as well as upon
stimulation with T1 related cytokines (Fig. 3.34; Fig. 3.35, A).  Tus the
activation status and the quantity of T cells during the acute phase of EAE
was investigated in the spinal cord (d14 p. i.;  Fig. 3.36).  While  Ryr3-/- and
control CD4+ T cells were found equally activated within the spinal cord, the
total  CD4+  cell  count  was  reduced  signifcantly.  However,  the  activation
status and quantity of CD4+ T cells was similar between Ryr3-/- and controls in
the  lymph  nodes  and  spleen  before  disease  onset  (d8  p.  i.;  Fig.  3.37),




Fig. 3.36 |  Activation status and quantity of infiltrating  Ryr3-/- T cells.  Ryr3-/- and control
mice (each n=3) were immunized against MOG35-55 peptide. Spinal cords were isolated from
PBS  perfused  animals  at  d14  p.  i.,  and  lymphocytes  were  isolated  by  gradient
centrifugation.  Cells  were  stained  and  analyzed  by  flow  cytometry  for  the  activation
markers CD25, CD69 and CD44 as well as the frequency of naïve T cells (CD62L expression).
For the analysis, cells were gated on the CD4+  population. The absolute number of CD4+
cells within the spinal cord was quantified with the help of counting beads and calculated
on the organ weight. Bars represent mean+SEM. Statistical analysis was performed using a
two-tailed Student’s t-test (*P ≤ 0.05).
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Fig. 3.37 | The quantity and activation status of T cells in the periphery is not altered in
Ryr3-/- animals  before  EAE  onset.  Ryr3-/- and  control  mice  (each  n=3)  were  immunized
against  MOG35-55 peptide.  Lymph  nodes  and  spleen  were  isolated  from  PBS  perfused
animals  at d8 p.  i.,  homogenized and depleted for erythrocytes.  Cells  were stained and
analyzed  by  flow  cytometry  for  the  activation  markers  CD25  and  CD69.  The  absolute
number  of  CD4+ cells  within lymph nodes  and spleen was quantified  with  the  help  of
counting beads and calculated on the organ weight. For the analysis, cells were gated on the
CD4+ population. Bars represent mean+SEM.
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3.4.7 T cell  migration  towards  Ryr3-/- astrocytes  conditioned
medium in vitro
To determine whether the lower chemokine production in Ryr3-/- astrocytes
afected  the  migration  capability  of  T cells,  in  vitro testing  by  means  of
transwell  migration  assays  was  employed  (Fig.  3.38).  Supernatants  from
stimulated  Ryr3-/- and  control  astrocytes  were  used  as  testing  agents  for
encephalitogenic WT T cells. It was observed that fewer T cells migrated to
supernatants of Ryr3-/- astrocytes that had been stimulated with IFN-γ/TNF-α
compared to control  supernatants.  Te same efect was seen in the assay
using  glutamate  stimulated  astrocyte  supernatants.  Migration  towards
supernatants of ATP treated Ryr3-/- astrocytes was comparable to that of ATP
stimulated control astrocytes.
Fig.  3.38 |  WT  T cells  transmigrate  less  towards  Ryr3-/- astrocytes  derived  supernatant
containing  medium.  Ryr3-/- and  control  astrocytes  were  stimulated  with  100 ng/ml
IFN-γ/TNF-α, 100 µM glutamate (Glu), 30 µM ATP or lef untreated (medium control; Med)
for 2 h.  Supernatants were collected and 1:10 dilutions were used as testing agents. WT
T cells were isolated from draining LNs of immunized animals at d9 p. i. and allowed to
transmigrate  for  5 h  (1×104 T cells/well).  The  frequency  of  transmigrated  cells  was
determined  by  flow  cytometry.  Bars  represent  the  mean  (+SEM)  of  three  independent
experiments. Statistical analysis  was performed using a two-tailed Student’s  t-test (*P ≤
0.05, ns P ≥ 0.05).
3.4.8 MHCII  expression  is  not  altered  in  Ryr3-/- astrocytes  and
microglia
Under neuroinfammatory conditions, microglia and under some conditions
also astrocytes up-regulate MHC-II molecules for optimal APC function and
T cell  restimulation  in  the  CNS  (RANSOHOFF AND ESTES,  1991).  However,
Ryr3-/- astrocytes and microglia did not difer from controls in their level of
MHC-II expression upon IFN-γ stimulation (Fig. 3.39).
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Fig.  3.39 |  MHCII  expression in  Ryr3-/- primary  astrocytes  and microglia  is  not  altered
compared to controls. MHCII expression was assessed in CD11b+ astrocytes (A) and F4/80+
microglia (B) by flow cytometry afer 24 h stimulation with 100 ng/ml IFN-γ.
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3.4.9 Dantrolene treated C57Bl/6 WT mice develop attenuated EAE
Te muscle relaxant dantrolene exhibits its efect by the selective blockage of
RyR1 and RyR3 (with preference for RyR1), and is used in the clinic for the
treatment of malignant hyperthermia (MH). As for its specifcity for Ryr1
and  RyR3—but  not  RyR2—it  came  into  focus  for  this  study  as  a
pharmacological tool to interfere with RyR signaling during EAE. A cohort
of WT C57Bl/6 mice was immunized against MOG35-55 peptide. Te mice were
treated  once  a  day  with  20 mg/kg  dantrolene  in  10 %  DMSO in  PBS,  or
received 10 % DMSO as  a  vehicle  control.  Te treatment was carried out
starting  on  the  day  of  immunization  and  was  terminated  when the  frst
clinical symptoms appeared in control mice (Fig. 3.40 A, C and D).  First
clinical symptoms appeared at about day 12 afer immunization in control
mice,  two days before  frst  signs  of  EAE were  observed  in  the  group of
dantrolene treated animals (Fig. 3.40, C). In the control group, the course of
EAE peaked on day 19 with an average score of about 6, whereas dantrolene
treated mice developed a delayed and signifcantly ameliorated disease (Fig.
3.40, A). It was found that weight loss occurred in both groups of mice, but
was less pronounced in dantrolene treated group of mice (Fig. 3.40, B). In
addition to the clinical data, histological analysis on the tissue collected d25
p. i.  showed  that  demyelination  and  the  severity  of  axon  damage  were




Fig.  3.40 A–D |  Dantrolene treated mice develop strongly atenuated and delayed EAE.
Mice (n=10 per group) were immunized against MOG35-55 peptide. Dantrolene solved in 10 %
DMSO was applied i.p. at 20 mg/kg daily starting at d0 until disease onset of mice of the
control group. Injections of 10 % DMSO served as controls. (A) EAE disease course, and (B)
weight change course of dantrolene treated mice (purple line) and DMSO treated mice (grey
line).  (C) Day of disease onset. (D) Percentage of disease free animals. In all  panels the
mean (+SEM) of two independent experiments is shown. Statistics were carried out using
the Mann–Whitney U test for clinical courses (A, B; **P ≤ 0.01) and a two-tailed Student’s t-
test (C; *P ≤ 0.05).
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Fig. 3.40 (E) and (F) | Demyelination and axonal loss are reduced in dantrolene treated
mice. Spinal cords (n=3 for each group) were isolated at the end of the observation period
(d25 p. i.) and used for parafin sections. (E) shows the evaluation of demyelination. Samples
were stained with luxol fast blue solution to detect myelin, combined with a periodic acid-
Schif  reaction  to  visualize  exposed  glycoproteins  in  the  deymelinated  regions.  The
percentage of demyelination was calculated for the area of the white mater. (F) shows the
evaluation of axonal degradation by means of Bielschowsky’s silver stain. The percentage of
axonal loss was calculated for the area of the white mater. For the statistical analysis, at
least five sections from the cervical, thoraic and lumbar segment were investigated for each
spinal cord. Bars represent mean (+SEM). Data were statistically tested using a two-tailed
Student’s t-test (**P ≤ 0.01). Representative images are shown from animals with a clinical
score of 7.0 (DMSO) and 3.0 (dantrolene treated).
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4 Discussion
4.1 Expression of RyRs in efector T cells
Present investigations on RyRs in C57Bl/6 mice started with the evaluation
of Ryr1 and Ryr3 mRNA expression in murine immune cells, including naïve
T cells, efector T cells, resting B cells, activated B cells and dendritic cells.
Ryr1 and Ryr3 mRNA was expressed in efector T cells, with notable higher
levels of Ryr1 mRNA rather than Ryr3. No copies of Ryr1 or Ryr3 mRNA were
found instead in naïve T or B cells and only minimal amounts of  Ryr1 or
Ryr3 mRNA were detected in dendritic cells (Fig. 3.1). RyRs are very large
proteins—with over one hundred exons—making them the largest known ion
channels. Even though the half-life is not known for RyR1 and RyR3, it is
estimated for about eight days for RyR2 (SANTONASTASI AND WEHRENS, 2006).
In  comparison,  the  half-life  of  beta-actin,  which  is  a  commonly  used
housekeeping gene, is about 24 h. It is thus very likely that sufcient mRNA
levels of RyRs may only be detectable in (fast) dividing cells when lots of
mRNA copies are produced like it happens during the proliferation of T cells,
but not in cells that are resting or in a steady state.
Te expression of RyR1 and RyR3 proteins in rat efector T cells, previously
shown by  CORDIGLIERI et al.  (2010), was confrmed in this study in mouse
efector T cells. Te kinetic of RyR1 and RyR3 expression in splenic T cells
was  determined  within  the  frst  96 h  upon  stimulation  with  either  anti-
CD3/CD28 antibodies or MOG35-55 peptide (Fig. 3.2). Tis result confrmed the
assumption that  Ryr mRNA is primarily detectable during phases of T cell
proliferation rather than in unstimulated cells. In a support of the real-time
PCR data, the expression of RyR1 and RyR3 proteins could be detected by
fuorescent staining in efector T cells (Fig. 3.3). 
4.2 Te role of RyR1 expression in T cells during
EAE
T cell activation relies on the fast increase in free intercellular Ca2+  that is
initially triggered by IP3Rs and most probably, RyRs. Te evidence of RyR1
and  RyR3  expression  in  rat  and  murine  efector  T cells  supported  this
hypothesis.  We  further  addressed  the  importance  of  RyR1  for  T cell
activation with  the  help  of  RyR knockout  mice.  Ryr1-/- (TAKESHIMA et al.,
1994), Ryr3-/- (TAKESHIMA et al., 1996) and  Ryr1-/-Ryr3-/- mice (IKEMOTO et al.,
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2008),  each  crossed  to  RFP  reporter  (expressed  from Rosa26  locus)  mice,
provided the basis for the current study. However  Ryr1 defcient,  but not
Ryr3,  mice  die  soon afer  birth.  However,  as  we were interested in RyR1
function in T cells, we bypassed these circumstances with the generation of
chimeric mice (fetal liver chimeras, FLCs), by reconstitution of irradiated WT
mice with embryonal  Ryr1-/- hematopoietic progenitor cells  (chapter 2.4.2
and Fig. 3.4). To generate a comparable condition for the analysis of  Ryr3
defcient or DKO T cells. Ryr1+/-Ryr3+/- mice were mated with Ryr1+/-Ryr3-/- and
embryos  of  appropriate  genotypes  were  used  for  FLC  production.  Te
distribution  of  the  genotypes  among  the  fetuses  followed  the  Mendelian
rules and resulted in 37.5 % controls and  Ryr3-/- single KOs, but only 12.5 %
Ryr1-/- single KOs and double KOs. Tis has complicated generation of FLCs,
as not in every mating all genotypes were present. In any case, expression of
the RFP fuorescent reporter gene by the respective KO cells allowed us the
validation  of  sufcient  hematopoietic  cell  reconstitution  that  for  B  cell
lineage usually exceeded 80 %, whereas for peripheral T cells remaining host
derived population ranged 25-40%. Tis underscores the need for congenic
marker (RFP) to restrict the analysis to donor derived T cells. Comparing to
control  chimeras,  the  reconstitution  with  Ryr1-/-  hematopoietic  progenitor
cells did not infuence the weight or cellularity of thymus and spleen (Fig.
3.5). Neither it altered T cell development in the thymus (Fig. 3.6), nor the
composition  of  the  peripheral  immune  system  (Fig.  3.7).  Te  same  was
observed for  Ryr3-/- and  Ryr-DKO. Altogether, Ryr1 and Ryr3 seem not to
play  a  major  role  during  T  cell  development,  which  is  concordant  with
detectable expression of these receptors only in diferentiated efector but
not naïve T lymphocytes. 
Binding of peptide-MHC complexes by TCRs of naïve T cells results in T cell
activation  (JENKINS et  al.,  2001),  followed  by  rapid  proliferation  and
diferentiation  into  efector  cells  (SEDER AND AHMED,  2003).  We  analyzed
T cells  from Ryr1-/-,  Ryr3-/- and  Ryr-DKO→WT  FLCs  for  their  ability  to
proliferate in response to anti-CD3 or anti-CD3/CD28 antibody stimulation
(Fig.  3.9).  Ryr-KO FLCs  were  compared  with  heterozygous  control  FLCs
(Ryr1+/-Ryr3+/-→WT) and showed decreased proliferation in response to TCR
stimulation.  Our  results  were  supported  by  the  data  of  our  collaborating
partners from the lab of Dr. A. Guse (UKE, Hamburg) on the role of RyR1 in
calcium signaling during T cell activation (WOLF et al., 2015, manuscript in
revision and Fig. 3.8): WOLF and colleagues demonstrated that Ryr1-/- played
crucial  role  for  the  formation  of  early,  initial  intracellular  Ca2+  signals  in
T cells upon stimulation of TCR. Tis fnding is in agreement with results
that indicated a possible role of RyR1 for efector T cell activation in the rat
(CORDIGLIERI et al., 2010). However, the additional knockout of  Ryr3 had no
further atenuating efect on T cell proliferation (Fig. 3.9), and T cells lacking
Ryr3 alone  did  not  proliferate  diferently  from  controls  (Fig.  3.9).  Tese
results again ft to the mRNA expression data and we concluded that RyR1—
in contrast to RyR3—is the more important isoform for T cell activation.
Afer priming and proliferation in the lymph nodes, T cells enter the blood
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circulation to search for antigen (GOVERMAN,  2009).  We assumed that the
reduced ability of Ryr1-/- T cells to proliferate in response to TCR stimulation
would also infuence the clinical outcome of EAE. We induced EAE in Ryr1-/-
→WT FLCs by active immunization against MOG35-55 peptide (Fig. 3.10) and
observed that mice with Ryr1 defciency in hematopoietic cells developed an
atenuated disease course. We also observed a slight delay during the acute
phase of EAE. However, the day of disease onset was not signifcantly altered
in Ryr1-/-→WT FLCs. Since the majority of T cells in Ryr1-/-→WT FLCs were
lacking Ryr1, the delayed and atenuated disease course could be explained
by a fewer number of postactivated T cells that leave the LNs where they
proliferate upon immunization. Tis was supported by the lower frequency
of T cells found in the CNS of  Ryr1-/-→WT FLCs at d14 of the disease and
was  accompanied  by  lower  expression  of  the  surface  activation  markers
CD25 and CD69 on these cells (Fig. 3.13). Future experiments will show if
the atenuation of EAE in Ryr1-/-→WT FLCs is restricted to the defciency of
RyR1 in T cells. Even though the mRNA data concerning the expression of
Ryr1 in immune cells do not support this possibility, it cannot be generally
excluded that RyR1 plays functions in other hematopoietic cells. A potential
objective for investigations might be the antigen presentation to T cells by
dendritic cells in the LNs, since we showed that Ryr1 mRNA is expressed in
these cells, even though at minimal levels (Fig. 3.1).
Next, EAE was induced in Ryr-DKO→WT FLCs, which developed a similar
atenuated disease course as observed in Ryr1-/-→WT FLCs (Fig. 3.11). While
EAE symptoms were signifcantly reduced in  Ryr-DKO→WT FLCs at the
peak of EAE, the disease course showed no signs of a delay during the acute
phase. In addition, some mice partially recovered during the chronic phase,
which was not observed in Ryr1-/-→WT FLCs. Tis resulted in considerable
deviations  in  the  mean  clinical  score,  that  complicates  conclusive
interpretation of  the EAE results  in the chronic phase of  Ryr-DKO→WT
experiments. However, T cells from  Ryr-DKO→WT FLCs were found in a
lower number and also less activated in the CNS (Fig. 3.13). Anyway, the
efect of the additional Ryr3 ablation was rather minimal. Tis became even
more clear when we analysed EAE in Ryr3-/-→WT FLCs. Tough these mice
developed  an  EAE  that  was  by  tendency  milder  than  in  controls  at  the
chronic stage of disease (Fig. 3.12), the diference to controls was minimal
and  not  statistically  signifcant.  Te  results  supported  the  in  vitro
observations (Fig. 3.36 and chapter 3.3.5, discussed later) that Ryr3 deletion
alone does not have a strong impact on T cell function and thus on the EAE
development.
We assume that amelioration of EAE symptoms in  Ryr1-/-→WT FLCs was
mediated by  Ryr1 deletion in T cells. Future experiments will  show if this
holds true for T cell  activation in the lymph nodes,  thus leading to fewer
T cells that home for the CNS, or T cell reactivation within the CNS.
Te generation of fetal liver chimeras allowed us the investigation of  Ryr1
deletion,  even  though  we  could  not  breed  Ryr1-/- mice.  However,  since
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reconstitution of hematopoietic cells was never 100 %, we could not rule out
that our results were infuenced by the remaining endogenous T cells that
are WT for Ryr1. So, prospective experiments should be performed in OT II
host mice whose T cells are specifc against the non-self antigen ovalbumine
(OVA) and do not respond to MOG35-55 immunization. By that, an infuence of
remaining endogenous T cells, that potentially harbor MBP-specifc ones,  on
the outcome of EAE should be eliminated. A second approach to study RyR1
function would be the generation of a conditional KO for  Ryr1. Tis would
avoid early lethality and allow the investigator to control the usage of Ryr1-/-
at diferent stages of EAE in specifc populaions. Since we were interested
specifcally in T cell function, a T cell specifc KO for the  Ryr1 gene would
further specify the role of RyR1 in T cells during EAE.
4.3 Te role of RyR3 in EAE
Homozygous Ryr3-KO mice are viable and fertile, allowing EAE experiments
in adult non-chimeric animals. Mice with whole-body Ryr3 deletion showed
a  signifcantly  ameliorated  EAE course  afer  active  immunization  against
MOG35-55  peptide  compared  to  Ryr3
+/- controls  (Fig.  3.16).  Heterozygous
litermates served as suitable control animals since we found no diferences
in the clinical outcome of EAE between Ryr3+/- and Ryr3+/+ mice (not shown).
Interestingly,  the  results  difered  from  the  EAE  observed  in  Ryr3-/-→WT
FLCs and we assumed that deletion of Ryr3 in cells that did not derive from
the hematopoietic lineage were responsible for disease atenuation.
Considerable  expression  of  RyR3  was  reported  for  the  mammalian  brain
(MURAYAMA AND OGAWA, 1996), and we confrmed expression of Ryr3 mRNA
for the total brain and the spinal cord tissues of C57Bl/6 mice (Fig. 3.14). We
investigated whether the observed atenuation of EAE in Ryr3-/- mice was due
to  the  deletion  of  Ryr3 in  the  CNS  and  so  we  generated  bone  marrow
chimeras (BMCs) by the transfer of Ryr3+/+ bone marrow cells into irradiated
Ryr3-/- recipient mice. EAE in these animals proceeded similar to that of germ
line Ryr3-/- mice (Fig. 3.15). In any case, mice shared an identical onset and
acute phase of EAE with the respective controls,  while disease proceeded
signifcantly milder at the peak and during the chronic phase of EAE.
Histological analysis revealed fewer infltrating T cells and macrophages in
the CNS of Ryr3-/- mice (Fig. 3.17). We also detected fewer reactive microglia
at the infammatory sites (Fig. 3.18) and observed less demyelination as well
as  axonal  loss  (Fig.  3.19).  Interestingly,  while  the  frequency  of  CNS
infltrating T cells was signifcantly lower in Ryr3-/- mice, the activation status
of T cells was similar to that of controls (Fig 3.36) when we investigated the
situation in the acute phase of EAE.
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Tymus and spleen developed similar in  Ryr3-/- mice, and no alterations in
thymic  T cell  development  were  observed  (Fig.  3.22  and  Fig.  3.23).
However, we found a shif in the ratio of CD4+ / CD8+  T cells towards the
cytotoxic T cell population in lymph nodes and spleen of Ryr3-/-. Apart from
that, the composition of the immune system in lymph nodes and spleen of
Ryr3-/- mice was similar to that of controls (Fig. 3.24 and Fig. 3.25). As well
as  observed  in  Ryr3-/-→WT  FLCs  (Fig.  3.12),  T lymphocytes  from  Ryr3-/-
mice  proliferated  similar  to  controls  upon  TCR stimulation  in  vitro  (Fig.
3.26).  We  could  confrm  this  by  the  analysis  of  in  vivo proliferation  of
transferred MOG-specifc  Ryr3-/-  T cells  in the draining lymph nodes afer
immunization (Fig. 3.27).  Tere was also no impairment in the ability of
Ryr3-/- T cells  to  recall  antigen  in  vitro afer  previous  priming  in  the
secondary  lymphoid  organs  (Fig.  3.29).  Te  later  result  matched  to
unchanged T cell numbers in lymph nodes and spleen one day before EAE
onset (Fig. 3.37). By transfer of MOG-specifc 2D2  Ryr3-/- T cells into OT II
mice (homozygous tg/tg genotype) we tested whether or not specifc ablation
of  Ryr3 in T cells would afect EAE development upon immunization (Fig.
3.28).  In  OT II  mice  OVA-specifc  T cells  do  not  respond  to  MOG
immunization  making  the  animals  resistant  to  active  EAE  unless
supplemented  with  exogenous  T  cells.  Under  these  conditions,  EAE
development would be exclusively driven by the transferred T cells. On the
other  hand,  OT II  mice  harbor  a  normal  immune  system  to  assure  for
example  normal  priming  of  T cells  in  the  lymph  nodes  or  antigen
presentation in the CNS. However, we observed no signifcant diferences in
the EAE between mice that received MOG-specifc Ryr3-/- or control T cells.
We concluded, that Ryr3 deletion did not afect the proliferative response of
T cells upon TCR dependent stimulation, either  in vitro or  in vivo, or their
ability  to  leave  the  lymphoid  organs  in  order  to  home  for  the  CNS.
Furthermore we demonstrated that  Ryr3-/- T cells were not altered in their
activation status afer restimulation in the CNS.
Spontaneous EAE is of great advantage to study autoimmune CNS disease
without  active  immunization  or  transfer  of  in  vitro activated
encephalitogenic  T cell  blasts.  It  results  from the  presence  of  T cells  and
B cells that are both specifc for the same autoantigen MOG. We crossed our
TCRMOG×Ryr3-/- mice to IgHMOG  mice to investigate spontaneous EAE in the
context  of  Ryr3 defciency.  We  demonstrated  that  Ryr3-/-×TCRMOG×IgHMOG
mice  developed  EAE  less  frequently  and  later  in  life  than  Ryr3+/-
×TCRMOG×IgHMOG  control  mice.  Furthermore,  Ryr3  defcient  animals  had 
reduced EAE severity (Fig. 3.20) If we assume that  Ryr3 deletion in T cells
does  not  afect  the  clinical  outcome  of  EAE,  this  result  seemed  to  be
surprising at frst glance, since spontaneous EAE strongly relies on T cell—
B cell  interactions. However, also in spontaneous model,  Ryr3 was deleted
systemically,  and  not  specifcally  in  T cells.  So  actually,  the  clinical  data
indirectly supported our initial hypothesis that deletion of Ryr3 in cells of the
CNS mediated the observed EAE atenuation. 
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4.4 Te importance of RyR3 in astrocytes
Astrocytes are the major population of glia cells in the CNS and are involved
in numerous processes within the CNS, such as brain homeostasis, neuronal
support  and  the  recycling  of  excess  neurotransmiters.  Together  with
endothelial cells, astrocytes are also involved in maintaining the integrity of
the blood-brain barrier. Tere, astrocytes form specialized endfeet that are in
close  contact  to  the  intraparenchymal  blood  vessels.  In  case  of  smaller
injuries  or  infections,  astrocytes  may  become  activated  by  infammatory
factors such as cytokines and release neuromodulators such as chemokines
themselves  to  recruit  microglia  and  circulating  immune  cells  to  the
pathological site. During severe neuroinfammation the sustained release of
pro-infammatory cytokines and chemokines may allow peripheral immune
cells, that were recruited to the CNS by sensing chemokine gradients, the
migration across the blood-brain barrier, thereby supporting the generation
of chronic neuroinfammatory diseases.
Activated astrocytes respond with an increase of intracellular Ca2+  that can
spread  troughout  the  astrocytic  network  in  oscillatory  waves  via  gap
junctions,  thereby  triggering  the  activation  of  neighboring  astrocytes.  In
order  to  test  whether  or  not  RyR3 contributes  to  the  generation  of  Ca2+
signals in cultures of primary astrocytes, we induced strong Ca2+  signals by
the application of ATP and measured the Ca2+  response by subcellular Ca2+
imaging (Fig. 3.31) Astrocytes responded with a fast and sudden increase of
intracellular Ca2+  to ATP, followed by oscillating Ca2+  signals in some cells.
However, the Ca2+  response was atenuated in astrocytes lacking Ryr3. Tis
was supported by the fndings that Ca2+  dependent release of the common
neurotransmiter glutamate was reduced in Ryr3-/- astrocytes upon activation.
Te  sustained  production  of  chemokines  under  infammatory  conditions
plays a key role for the manifestation of chronic neuroinfammatory diseases,
such as EAE or MS. We tested whether deletion of Ryr3 atenuated the ability
of  astrocytes  to  produce  certain  chemokines,  including  CCL2,  CCL5  and
CXCL10, which represent important chemoatractants for the recruitment of
T cells and monocytes. In fact, production of these chemokines was notably
reduced in Ryr3-/- astrocytes upon stimulation with the pro-infammatory and
CD4+ T cell related cytokines IFN-γ and TNF-α. (Fig. 3.34). We confrmed the
atenuated ability of Ryr3-/- astrocytes to produce chemokines also under EAE
conditions  (Fig.  3.35).  Te  lower  frequency  of  T cells  within  the
corresponding spinal cords (Fig. 3.36) supported the hypothesis that RyR3 is
highly involved in the activation of astrocytes and their ability to produce
and secrete chemokines for the recruitment of immune cells, without directly
afecting the activation status of T cells. We demonstrated with the help of
transwell  migration  assays  that  the  reduction  in  chemokine  secretion  by
Ryr3-/- astrocytes  was  sufcient  to  atenuate  the  ability  of  T cells  to
transmigrate  across  a  membrane  towards  the  supernatants  of  IFN-γ  and
85
Discussion
TNF-α stimulated Ryr3-/- astrocytes (Fig. 3.38).
Earlier reports demonstrated the ability of astrocytes to function as antigen
presenting  cells  in  the  context  of  MHC-II  expression  under
neuroinfammatory  conditions.  We  could  detect  similar  levels  of  MHC-II
expression in Ryr3-/- and control astrocytes and assumed that atenuation of
Ryr3-/- EAE was not mediated by the disability of  Ryr3-/- astrocytes to act as
antigen  presenting  cells  in  the  CNS  (Fig.  3.39).  We  found  that  MHC-II
expression  by  microglia  was  not  altered  by  Ryr3 deletion,  assuming  that
antigen presentation was not further afected by the defciency of Ryr3-/-.
4.5 Pharmacological approaches to study RyRs
Pharmacological targeting of the NAADP signaling pathway has been used
in rat efector T cells and Lewis rat adoptive transfer EAE.  CORDIGLIERI and
colleagues showed that the treatment with BZ194, an analogue of nicotinic
acid, ameliorates active and passive EAE in Lewis rats (2010). However, this
compound has not yet been tested in clinical trials of any kind.
Inhibition of RyR function by the muscle relaxant dantrolene is the common
therapy  for  patients  sufering  from  malignant  hyperthermia.  We  took
advantage from the specifcity of dantrolene for the RyR1 and RyR3 isoform
and  applied  it  to  WT  mice  afer  immunization  against  MOG35-55  peptide.
Dantrolene treated mice developed a strongly atenuated EAE course (Fig.
3.40). In fact, the reduction of clinical symptoms was greater than observed
in the respective KO chimera experiments. Tis may be due cumulative efect
of inhibition of Ryr1 in T cells and Ryr3 in astrocytes. Furthermore, in fetal
liver chimeric mice a substantial fraction of recipient-derived, and thus Ryr1-
profcient T cells, may account for a less pronounced EAE ameliorating efect
comparing  to  drug  treatment  efect.  As  the  dantrolene  was  applied
systemically, efects of this drug on other cells or organs cannot be ruled out.
Future experiments using the treatment of Ryr1-KO FLCs and Ryr3 germline
KO mice and respective controls with dantrolene should help to clarify the
inhibition of which RyR isotype has a dominant role in the therapeutic efect




Our study suggests a putative role for RyRs in MOG35-55 peptide EAE in two
diferent ways: While the RyR1 isoform is highly expressed in T cells and
obviously contributes  to  T cell  activation  in  vitro as  well  as  in  vivo,  Ca2+
signaling  via RyR3  crucially  contributes  to  chemokine  production  in
astrocytes during the onset and acute phase of EAE, thereby mediating T cell
and monocyte recruitment to the CNS.
Fig.  4.1  | Suggested  roles  of  RyR1  and  RyR3  during  the  development  of  autoimmune
diseases of the CNS: While RyR1 contributes to T cell activation in the periphery and/or in
the  CNS,  RyR3  is  expressed  in  astrocytes  where  it  is  involved  in  the  production  of
chemoatractants for T cell and monocyte recruitment.
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T cell  activation requires  the elevation of  free  intracellular  Ca2+,  which is
mediated  by  certain  Ca2+ release  channels.  During  the  last  years  it  has
become increasingly clear that ryanodine receptors (RyRs) play a crucial role
for the generation of intracellular Ca2+ signals in T cells and thus contribute
to T cell activation.
Te development of CNS autoimmune diseases like multiple sclerosis (MS) or
its animal model experimental autoimmune encephalomyelitis (EAE) relies
on  the  activation  of  auto-reactive  T cells  that  are  directed  against  CNS
antigens.  In  the  present  study  we  addressed  the  question  how  RyRs
contribute to the development of autoimmune diseases. We found that the
RyR1  isoform  is  expressed  in  efector,  but  not  in  naïve  mouse  cells.  By
genetic deletion of the Ryr1 gene we demonstrated contribution of RyR1 to
Ca2+ signaling  and  TCR  dependent  T cell  proliferation.  Tis  presumably
caused the observed EAE atenuation in Ryr1-/- fetal liver chimeras.
Amelioration of EAE was observed in mice with a whole-body knockout for
Ryr3.  However,  in contrast to RyR1,  we excluded a major role of  Ryr3 in
T cells  using chimeric mice and T cell  transfer experiments.  However,  we
demonstrated a pivotal role for RyR3 in astrocytes. Ryr3 defcient astrocytes
showed alterations in Ca2+ signaling and defcits in chemokine production
upon infammatory stimuli in vitro, but also during EAE in the infamed CNS
tissue, thus limiting the infltration of immune cells and CNS histopathology.
In addition we showed that pharmacological inhibition of RyRs atenuated
EAE disease. In summary, our study provides evidence that RyRs play critical
roles during EAE—RyR1 in T cells and RyR3 in astrocytes—and thus may be
targets for therapeutic treatment of autoimmune CNS diseases.
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